<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523414008368</prism:url><dc:identifier>doi:10.1016/j.ejmech.2014.09.018</dc:identifier><eid>1-s2.0-S0223523414008368</eid><prism:doi>10.1016/j.ejmech.2014.09.018</prism:doi><pii>S0223-5234(14)00836-8</pii><dc:title>4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>86</prism:volume><prism:startingPage>664</prism:startingpage><prism:endingPage>675</prism:endingpage><prism:pageRange>664-675</prism:pagerange><dc:format>text/xml</dc:format><prism:coverDate>2014-10-30</prism:coverdate><prism:coverDisplayDate>30 October 2014</prism:coverdisplaydate><prism:copyright>Copyright © 2014 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Puig de la Bellacasa, Raimon</dc:creator><dc:creator>Roué, Gaël</dc:creator><dc:creator>Balsas, Patricia</dc:creator><dc:creator>Pérez-Galán, Patricia</dc:creator><dc:creator>Teixidó, Jordi</dc:creator><dc:creator>Colomer, Dolors</dc:creator><dc:creator>Borrell, José I.</dc:creator><dc:description>
                  A new family of 4-aminopyrido[2,3-d]pyrimidines active against non-Hodgkin's lymphomas (NHLs) is described. Among these compounds, 19 inhibits the most upstream tyrosine kinases in the B cell receptor (BCR) signaling pathway which are involved in the mature B cell neoplasms. Thus, 19 showed antiproliferative activity at 24 h and 48 h against a panel of 20 NHLs cell lines with GI50 ranging from 1.3 to 6.9 μM at 24 h, and 1.4–7.2 μM at 48 h, being this effect related to a significant (20–90%) inhibition of the phosphorylation of the BCR-related kinases Btk, Syk, and Lyn. Most importantly, 19 was able to induce a 63% reduction in Rec-1 cell proliferation, which was significantly greater than the 31% and 3% blockade of proliferation observed after cell treatment with R406, a Syk inhibitor, and ibrutinib, a Btk inhibitor, respectively. The computational blind docking and ligand binding within the pockets of Btk, Syk and Lyn kinases showed that compound 19 presents the same kind of interactions of described cocrystallized inhibitors.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Non-Hodgkin's lymphomas</dcterms:subject><dcterms:subject>B-cell receptor</dcterms:subject><dcterms:subject>Kinases</dcterms:subject><dcterms:subject>Small molecule inhibitor</dcterms:subject><dcterms:subject>7-oxopyrido[2,3-d]pyrimidines</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523414008368" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523414008368" rel="scidir"/></link></coredata><objects><object ref="si1" category="thumbnail" type="ALTIMG" multimediatype="GIF image file" mimetype="image/gif" width="779" height="20" size="2944">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-si1.gif?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="356" height="256" size="17612">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="388" height="350" size="28424">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="401" height="200" size="23395">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="387" height="358" size="37209">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="791" height="944" size="204029">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="639" height="472" size="94407">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="532" height="270" size="29833">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr10.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="354" height="499" size="32779">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="385" height="236" size="25458">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="606" height="256" size="27355">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="387" height="77" size="10720">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="387" height="364" size="31573">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="157" size="5961">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="181" height="163" size="3101">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="109" size="5013">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="177" height="164" size="4599">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr9.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="137" height="163" size="9070">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="162" size="10353">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="111" size="3578">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr10.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="116" height="164" size="2910">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="134" size="4119">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="92" size="2902">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="44" size="2027">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="174" height="164" size="4052">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="1703768">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523414008368-mmc1.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>84907815262</scopus-id><scopus-eid>2-s2.0-84907815262</scopus-eid><pubmed-id>25222877</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/84907815262" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20140906">2014-09-06</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20140906">2014-09-06</xocs:available-online-date>
      <xocs:ew-transaction-id>2014-10-03T06:44:22</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523414008368</xocs:eid>
      <xocs:pii-formatted>S0223-5234(14)00836-8</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523414008368</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2014.09.018</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523414X00140</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20150514">2015-05-14T05:55:44.535656-04:00</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20141030</xocs:date-search-begin>
      <xocs:year-nav>2014</xocs:year-nav>
      <xocs:indexeddate epoch="1410019984">2014-09-06T16:13:04.832055Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body mmlmath acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast grantnumber grantsponsor highlightsabst orcid otherkwds primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>86</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>86</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 86</xocs:vol-iss-suppl-text>
      <xocs:sort-order>53</xocs:sort-order>
      <xocs:first-fp>664</xocs:first-fp>
      <xocs:last-lp>675</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>664</xocs:first-page>
         <xocs:last-page>675</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20141030</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>30 October 2014</xocs:cover-date-text>
      <xocs:cover-date-start>2014-10-30</xocs:cover-date-start>
      <xocs:cover-date-year>2014</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Original articles</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>Copyright © 2014 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>4AMINO2ARYLAMINO626DICHLOROPHENYLPYRIDO23DPYRIMIDIN78HONESBCRKINASEINHIBITORSFORBLYMPHOIDMALIGNANCIES</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>PUIGDELABELLACASA</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>R</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biological evaluation of synthesized compounds</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Development and biological evaluation of a water soluble analogue of compound <ce:bold>16</ce:bold>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Computational blind docking studies of compound <ce:bold>19</ce:bold>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Experimental</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Synthesis and characterization of compounds</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (<ce:bold>14a</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>4-Amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (<ce:bold>16</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>4-Amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-5,6-dihydropyrido[2,3-d]pyrimidin-7(8H)-one (<ce:bold>15</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2,4-Diamino-6-(2,6-dichlorophenyl)-5,6-dihydropyrido[2,3-d]pyrimidin-7(8H)-one (<ce:bold>12b</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>6-(2,6-Dichlorophenyl)-N-phenyl-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diamine (<ce:bold>17</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>4-Amino-2-(4-bromophenylamino)-6-(2,6-dichlorophenyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (<ce:bold>18</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>4-Amino-6-(2,6-dichlorophenyl)-8-methyl-2-[4-(4-methylpiperazin-1-yl)phenylamino]-pyrido[2,3-d]pyrimidin-7(8H)-one (<ce:bold>19</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.9</xocs:item-toc-label>
                  <xocs:item-toc-section-title>4-Amino-6-(2,6-dichlorophenyl)-8-methyl-2-[4-(2-morpholinoethylamino)-phenylamino]-pyrido[2,3-d]pyrimidin-7(8H)-one (<ce:bold>20</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.10</xocs:item-toc-label>
                  <xocs:item-toc-section-title>4-Amino-6-(2,6-dichlorophenyl)-8-methyl-2-[4-(2-morpholinoethoxy)-phenylamino]-pyrido[2,3-d]pyrimidin-7(8H)-one (<ce:bold>21</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biology</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Kinase inhibition profile</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Assays in non-Hodgkin's lymphomas cell lines and on the activity of BCR kinases</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Cytotoxicity assay in PBMCs isolated from healthy donors</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Statistical analysis</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Computational studies</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgment</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>NOGAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1803</xocs:ref-first-fp>
            <xocs:ref-last-lp>1811</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>TILLY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>v172</xocs:ref-first-fp>
            <xocs:ref-last-lp>v174</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>KRIDEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>3424</xocs:ref-first-fp>
            <xocs:ref-last-lp>3431</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>JARES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>3416</xocs:ref-first-fp>
            <xocs:ref-last-lp>3423</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>ZENZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>37</xocs:ref-first-fp>
            <xocs:ref-last-lp>50</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>YOUNG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>229</xocs:ref-first-fp>
            <xocs:ref-last-lp>243</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>QUINTASCARDAMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>655</xocs:ref-first-fp>
            <xocs:ref-last-lp>665</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>HANTSCHEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>13283</xocs:ref-first-fp>
            <xocs:ref-last-lp>13288</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>AMREIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>2977</xocs:ref-first-fp>
            <xocs:ref-last-lp>2986</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>FRIEDBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>2578</xocs:ref-first-fp>
            <xocs:ref-last-lp>2585</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>ADVANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>88</xocs:ref-first-fp>
            <xocs:ref-last-lp>94</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>BYRD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>32</xocs:ref-first-fp>
            <xocs:ref-last-lp>42</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>507</xocs:ref-first-fp>
            <xocs:ref-last-lp>516</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>WU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>6368</xocs:ref-first-fp>
            <xocs:ref-last-lp>6372</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>MARTINEZTEIPEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>436</xocs:ref-first-fp>
            <xocs:ref-last-lp>448</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>VICTORY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1985</xocs:ref-pub-year>
            <xocs:ref-first-fp>1135</xocs:ref-first-fp>
            <xocs:ref-last-lp>1141</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>PEREZPI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>581</xocs:ref-first-fp>
            <xocs:ref-last-lp>591</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>GALVE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>639</xocs:ref-first-fp>
            <xocs:ref-last-lp>649</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>BOSCHELLI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>4365</xocs:ref-first-fp>
            <xocs:ref-last-lp>4377</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="oref1"/></xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>ROUE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1270</xocs:ref-first-fp>
            <xocs:ref-last-lp>1279</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>KUGLSTATTER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>428</xocs:ref-first-fp>
            <xocs:ref-last-lp>436</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>LOVERING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>657</xocs:ref-first-fp>
            <xocs:ref-last-lp>664</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>WILLIAMS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>284</xocs:ref-first-fp>
            <xocs:ref-last-lp>291</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="oref2"/></xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>67</xocs:ref-first-fp>
            <xocs:ref-last-lp>73</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>IVERSEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>247</xocs:ref-first-fp>
            <xocs:ref-last-lp>252</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>ROSICH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>5278</xocs:ref-first-fp>
            <xocs:ref-last-lp>5289</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>SANNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>57</xocs:ref-first-fp>
            <xocs:ref-last-lp>61</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>MORRIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>2785</xocs:ref-first-fp>
            <xocs:ref-last-lp>2791</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>GASTEIGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1980</xocs:ref-pub-year>
            <xocs:ref-first-fp>3219</xocs:ref-first-fp>
            <xocs:ref-last-lp>3228</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-normalized-srctitle>MOLECULAROPERATINGENVIRONMENTMOE</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>PUIGDELABELLACASAX2014X664</xocs:refkey3>
         <xocs:refkey4lp>PUIGDELABELLACASAX2014X664X675</xocs:refkey4lp>
         <xocs:refkey4ai>PUIGDELABELLACASAX2014X664XR</xocs:refkey4ai>
         <xocs:refkey5>PUIGDELABELLACASAX2014X664X675XR</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(14)00836-8</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523414008368</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523414008368</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2014.09.018</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2014-10-03T06:40:12.777196-04:00</xocs:timestamp>
         <xocs:cover-date-start>2014-10-30</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/MAIN/application/pdf/bd45e47e78288831bd8f0f8c19341f83/main.pdf</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/MAIN/application/pdf/bd45e47e78288831bd8f0f8c19341f83/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>2194465</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>12</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523414008368-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/PREVIEW/image/png/365d909812f81021d0774f7f9b7ea0ed/main_1.png</xocs:ucs-locator>
                     <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/PREVIEW/image/png/365d909812f81021d0774f7f9b7ea0ed/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>59478</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-si1.gif</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/STRIPIN/image/gif/25869996ccd69f2662a20da68b3566eb/si1.gif</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/STRIPIN/image/gif/25869996ccd69f2662a20da68b3566eb/si1.gif</xocs:ucs-locator>
               <xocs:file-basename>si1</xocs:file-basename>
               <xocs:filename>si1.gif</xocs:filename>
               <xocs:extension>gif</xocs:extension>
               <xocs:filesize>2944</xocs:filesize>
               <xocs:pixel-height>20</xocs:pixel-height>
               <xocs:pixel-width>779</xocs:pixel-width>
               <xocs:attachment-type>ALTIMG</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr3/DOWNSAMPLED/image/jpeg/a86994a34986d1f129295b1c94e4091f/gr3.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr3/DOWNSAMPLED/image/jpeg/a86994a34986d1f129295b1c94e4091f/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>17612</xocs:filesize>
               <xocs:pixel-height>256</xocs:pixel-height>
               <xocs:pixel-width>356</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr4/DOWNSAMPLED/image/jpeg/5fcabfea26e27b7506809f184ac2a31a/gr4.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr4/DOWNSAMPLED/image/jpeg/5fcabfea26e27b7506809f184ac2a31a/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>28424</xocs:filesize>
               <xocs:pixel-height>350</xocs:pixel-height>
               <xocs:pixel-width>388</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/fx1/DOWNSAMPLED/image/jpeg/f39b16247126258c2bd81ede69466f4c/fx1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/fx1/DOWNSAMPLED/image/jpeg/f39b16247126258c2bd81ede69466f4c/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>23395</xocs:filesize>
               <xocs:pixel-height>200</xocs:pixel-height>
               <xocs:pixel-width>401</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr9/DOWNSAMPLED/image/jpeg/b82983acd75bde2c880d1fcee92e2e01/gr9.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr9/DOWNSAMPLED/image/jpeg/b82983acd75bde2c880d1fcee92e2e01/gr9.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>37209</xocs:filesize>
               <xocs:pixel-height>358</xocs:pixel-height>
               <xocs:pixel-width>387</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr7/DOWNSAMPLED/image/jpeg/e4a93ceffb8555e824da211d8ced8b8b/gr7.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr7/DOWNSAMPLED/image/jpeg/e4a93ceffb8555e824da211d8ced8b8b/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>204029</xocs:filesize>
               <xocs:pixel-height>944</xocs:pixel-height>
               <xocs:pixel-width>791</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr2/DOWNSAMPLED/image/jpeg/ee8da132b2734e99b8f117643773cf17/gr2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr2/DOWNSAMPLED/image/jpeg/ee8da132b2734e99b8f117643773cf17/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>94407</xocs:filesize>
               <xocs:pixel-height>472</xocs:pixel-height>
               <xocs:pixel-width>639</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr10/DOWNSAMPLED/image/jpeg/5cbe6757bb03b553c80ab0feb9196d4a/gr10.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr10/DOWNSAMPLED/image/jpeg/5cbe6757bb03b553c80ab0feb9196d4a/gr10.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>29833</xocs:filesize>
               <xocs:pixel-height>270</xocs:pixel-height>
               <xocs:pixel-width>532</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr6/DOWNSAMPLED/image/jpeg/980399089875ad477bc9cc097ea1acee/gr6.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr6/DOWNSAMPLED/image/jpeg/980399089875ad477bc9cc097ea1acee/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>32779</xocs:filesize>
               <xocs:pixel-height>499</xocs:pixel-height>
               <xocs:pixel-width>354</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr8/DOWNSAMPLED/image/jpeg/bc88ac5315aa7ee7465db467b7cb6c80/gr8.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr8/DOWNSAMPLED/image/jpeg/bc88ac5315aa7ee7465db467b7cb6c80/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>25458</xocs:filesize>
               <xocs:pixel-height>236</xocs:pixel-height>
               <xocs:pixel-width>385</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/sc1/DOWNSAMPLED/image/jpeg/8ebb37d131a2ae4bfa8fe4a7fa286878/sc1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/sc1/DOWNSAMPLED/image/jpeg/8ebb37d131a2ae4bfa8fe4a7fa286878/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>27355</xocs:filesize>
               <xocs:pixel-height>256</xocs:pixel-height>
               <xocs:pixel-width>606</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr1/DOWNSAMPLED/image/jpeg/c0a9c87f4a0ef173262e5f1b34e923b8/gr1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr1/DOWNSAMPLED/image/jpeg/c0a9c87f4a0ef173262e5f1b34e923b8/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>10720</xocs:filesize>
               <xocs:pixel-height>77</xocs:pixel-height>
               <xocs:pixel-width>387</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr5/DOWNSAMPLED/image/jpeg/aef544444fb345048775a77fbadb53e9/gr5.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr5/DOWNSAMPLED/image/jpeg/aef544444fb345048775a77fbadb53e9/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31573</xocs:filesize>
               <xocs:pixel-height>364</xocs:pixel-height>
               <xocs:pixel-width>387</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr3/THUMBNAIL/image/gif/59da5922a2dd11f5f75808633ad3ab3e/gr3.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr3/THUMBNAIL/image/gif/59da5922a2dd11f5f75808633ad3ab3e/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5961</xocs:filesize>
               <xocs:pixel-height>157</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr4/THUMBNAIL/image/gif/9e40763366fc38031f9d14dc45f6a322/gr4.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr4/THUMBNAIL/image/gif/9e40763366fc38031f9d14dc45f6a322/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3101</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>181</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/fx1/THUMBNAIL/image/gif/ebb8ec47f8a055881873093089163e4c/fx1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/fx1/THUMBNAIL/image/gif/ebb8ec47f8a055881873093089163e4c/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5013</xocs:filesize>
               <xocs:pixel-height>109</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr9/THUMBNAIL/image/gif/bdc3a26bb41b8f2557f566260920ecad/gr9.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr9/THUMBNAIL/image/gif/bdc3a26bb41b8f2557f566260920ecad/gr9.sml</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4599</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>177</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr7/THUMBNAIL/image/gif/1718fc34e43de10319320c48756c12b6/gr7.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr7/THUMBNAIL/image/gif/1718fc34e43de10319320c48756c12b6/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9070</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>137</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr2/THUMBNAIL/image/gif/ba8ca92456131f124df20585ce2f6082/gr2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr2/THUMBNAIL/image/gif/ba8ca92456131f124df20585ce2f6082/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10353</xocs:filesize>
               <xocs:pixel-height>162</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr10/THUMBNAIL/image/gif/7175bf177481945d6561ee92bb80a506/gr10.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr10/THUMBNAIL/image/gif/7175bf177481945d6561ee92bb80a506/gr10.sml</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3578</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr6/THUMBNAIL/image/gif/b811fe439c27702231a9d5ef235274ab/gr6.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr6/THUMBNAIL/image/gif/b811fe439c27702231a9d5ef235274ab/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2910</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>116</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr8/THUMBNAIL/image/gif/0c612ce13a43dcf1fbbb76c7b924d92b/gr8.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr8/THUMBNAIL/image/gif/0c612ce13a43dcf1fbbb76c7b924d92b/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4119</xocs:filesize>
               <xocs:pixel-height>134</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/sc1/THUMBNAIL/image/gif/edd9be6841dbc4cba74c045d831caeb5/sc1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/sc1/THUMBNAIL/image/gif/edd9be6841dbc4cba74c045d831caeb5/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2902</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr1/THUMBNAIL/image/gif/42ca23dbe9aaf05ba2f46873ce558c48/gr1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr1/THUMBNAIL/image/gif/42ca23dbe9aaf05ba2f46873ce558c48/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2027</xocs:filesize>
               <xocs:pixel-height>44</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/gr5/THUMBNAIL/image/gif/2fe26d4c2927779e2842d436b7565602/gr5.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/gr5/THUMBNAIL/image/gif/2fe26d4c2927779e2842d436b7565602/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4052</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>174</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523414008368-mmc1.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523414008368/mmc1/MAIN/application/pdf/f983218b3122a6b8a5cdeae6997e93f4/mmc1.pdf</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523414008368/mmc1/MAIN/application/pdf/f983218b3122a6b8a5cdeae6997e93f4/mmc1.pdf</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:filesize>1703768</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.2" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>7324</aid>
            <ce:pii>S0223-5234(14)00836-8</ce:pii>
            <ce:doi>10.1016/j.ejmech.2014.09.018</ce:doi>
            <ce:copyright type="full-transfer" year="2014">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Classical approach to pyrido[2,3-<ce:italic>d</ce:italic>]pyrimidines.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr1"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Dose and time response of the MCL cell lines Rec-1 and HBL-2 to compounds <ce:bold>14a</ce:bold>, <ce:bold>16</ce:bold>, <ce:bold>15</ce:bold>, <ce:bold>17</ce:bold>, and <ce:bold>12b</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr2"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Dose-dependent activity of <ce:bold>16</ce:bold> was evaluated on primary blood cells isolated from two healthy donors, exposed for 24 h to the compound. Cell viability was evaluated by cytofluorimetric determination of Annexin V staining. Values are referred to control (untreated cells).</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr3"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">Dose-effect of compound <ce:bold>19</ce:bold> on the phosphorylation status of the B-Cell receptor (BCR)-related kinases in the MCL cell line Rec-1 after 6 h of treatment, as assessed by western blot analysis of phospho-Syk and phospho-Lyn (A), and cytofluorimetric detection of phospho-Btk (B). β-actin was used as a loading control. <ce:italic>r</ce:italic> values indicate the relative mean fluorescence intensity between Btk-PE signal and isotypic control. Black and grey curves indicate untreated and compound 19-treated cells, respectively. Untreated control cells were used as calibrators (<ce:italic>r</ce:italic> = 1).</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">Growth inhibitory effect of compound <ce:bold>19</ce:bold> evaluated by MTT assay at 24 h and 48 h in MCL, CLL, FL, and DLBCL cell lines. GI<ce:inf loc="post">50</ce:inf> doses are shown for each cell line.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr5"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">(A) Comparative inhibitory effect of compound 19 versus ibrutinib (Ibrut) and the fostamatinib active metabolite R406 on the phosphorylation status of Syk, Lyn and Btk in the MCL cell line Rec-1, by western blot. β-actin was used as a loading control. (B) Growth inhibitory effect of compound <ce:bold>19</ce:bold>, ibrutinib and R406 evaluated by MTT assay at 24 h in the MCL cell line Rec-1.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr6"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">(A) Docking and ligand interactions of compound <ce:bold>19</ce:bold> in Btk binding pocket compared with 2-[4-(2-diethylamino-ethoxy)-phenylamino]-6-(4-fluorophenoxy)-8-methyl-8<ce:italic>H</ce:italic>-pyrido[2,3-<ce:italic>d</ce:italic>]pyrimidin-7-one (PDB ID: <ce:inter-ref xlink:href="pdb:3PJ2" id="intref0040" xlink:type="simple">3PJ2</ce:inter-ref>) <ce:cross-ref refid="bib22" id="crosref0365">[22]</ce:cross-ref> complexed with the Btk kinase domain (depicted in yellow). (B) Docking and ligand interactions of compound <ce:bold>19</ce:bold> in Syk binding pocket compared with <ce:italic>N</ce:italic>-(4-methyl-3-(8-methyl-7-oxo-2-(phenylamino)-7,8-dihydropyrido[2,3-<ce:italic>d</ce:italic>]pyrimidin-6-yl)phenyl)-3-(trifluoromethyl)benzamide (PDB: <ce:inter-ref xlink:href="pdb:3TUD" id="intref0045" xlink:type="simple">3TUD</ce:inter-ref>) <ce:cross-ref refid="bib23" id="crosref0370">[23]</ce:cross-ref> complexed with the Syk kinase domain (depicted in green). (C) Docking and ligand interactions of compound <ce:bold>19</ce:bold> in Lyn binding pocket compared with dasatinib (PDB: <ce:inter-ref xlink:href="pdb:2ZVA" id="intref0050" xlink:type="simple">2ZVA</ce:inter-ref>) <ce:cross-ref refid="bib24" id="crosref0375">[24]</ce:cross-ref> complexed with the Lyn kinase domain (depicted in purple).</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr7"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Chart 1</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">Dasatinib (<ce:bold>1</ce:bold>), fostamatinib (<ce:bold>2</ce:bold>), and ibrutinib (<ce:bold>3</ce:bold>).</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr8"/></ce:link>
            </ce:figure>
            <ce:figure id="fig9">
               <ce:label>Chart 2</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">Sublibrary of compounds around compound <ce:bold>12a</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr9"/></ce:link>
            </ce:figure>
            <ce:figure id="fig10">
               <ce:label>Chart 3</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0055" view="all">Second sublibrary of compounds around compound <ce:bold>16</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr10"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0060" view="all">Synthesis of 7-oxopyrido[2,3-<ce:italic>d</ce:italic>]pyrimidines <ce:bold>12</ce:bold>, <ce:bold>13</ce:bold>, and <ce:bold>14</ce:bold> from α,β-unsaturated esters <ce:bold>8</ce:bold> 
                     <ce:italic>via</ce:italic> pyridones <ce:bold>10</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:link locator="sc1"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl1" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="tspara0010" view="all">GI<ce:inf loc="post">50</ce:inf>(24 h) and GI<ce:inf loc="post">50</ce:inf>(48 h) of compounds <ce:bold>12a</ce:bold>, <ce:bold>14a</ce:bold>, <ce:bold>16</ce:bold>, <ce:bold>15</ce:bold>, <ce:bold>17</ce:bold>, and <ce:bold>12b</ce:bold> against the MCL cell lines Rec-1 and HBL-2.</ce:simple-para>
               </ce:caption>
               <tgroup cols="5">
                  <colspec colnum="1" colname="col1" colwidth="10*"/></colspec>
                  <colspec colnum="2" colname="col2" colwidth="21*"/></colspec>
                  <colspec colnum="3" colname="col3" colwidth="21*"/></colspec>
                  <colspec colnum="4" colname="col4" colwidth="21*"/></colspec>
                  <colspec colnum="5" colname="col5" colwidth="20*"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1">Compd.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col2" nameend="col3">HBL-2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">Rec-1</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">GI<inf loc="post">50</inf> at 24 h (μM ± SD)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">GI<inf loc="post">50</inf> at 48 h (μM ± SD)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">GI<inf loc="post">50</inf> at 24 h (μM ± SD)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">GI<inf loc="post">50</inf> at 48 h (μM ± SD)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>12a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">12.0 ± 0.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.7 ± 0.01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">52.3 ± 0.03</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>14a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">8.8 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">12.1 ± 0.01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>16</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.7 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.4 ± 0.04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.8 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.7 ± 0.01</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>15</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.7 ± 0.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">67.2 ± 0.01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.3 ± 0.02</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>17</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">7.5 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.4 ± 0.01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.0 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.3 ± 0.01</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>12b</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>100</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl2" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="tspara0015" view="all">Kinase inhibition profile of compounds <ce:bold>19</ce:bold>, <ce:bold>20</ce:bold>, and <ce:bold>21</ce:bold> was determined by measuring residual activity values (%) at a concentration of 10 μM of compounds <ce:bold>19</ce:bold>, <ce:bold>20</ce:bold>, and <ce:bold>21</ce:bold> in front of Btk, Lyn, and Syk kinases.</ce:simple-para>
               </ce:caption>
               <tgroup cols="4">
                  <colspec colnum="1" colname="col1" colwidth="33*"/></colspec>
                  <colspec colnum="2" colname="col2" colwidth="28*"/></colspec>
                  <colspec colnum="3" colname="col3" colwidth="28*"/></colspec>
                  <colspec colnum="4" colname="col4" colwidth="4*"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Compd.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Btk</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Lyn</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Syk</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>19</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">−1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">9</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">31</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>21</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="char" char=".">44</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl3" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 3</ce:label>
               <ce:caption id="cap0075">
                  <ce:simple-para id="tspara0020" view="all">Mean GI<ce:inf loc="post">50</ce:inf> values of <ce:bold>19</ce:bold> in MCL, CLL, FL and DLBCL cell lines at 24 and 48 h.</ce:simple-para>
               </ce:caption>
               <tgroup cols="5">
                  <colspec colnum="1" colname="col1" colwidth="15*"/></colspec>
                  <colspec colnum="2" colname="col2" colwidth="20*"/></colspec>
                  <colspec colnum="3" colname="col3" colwidth="20*"/></colspec>
                  <colspec colnum="4" colname="col4" colwidth="20*"/></colspec>
                  <colspec colnum="5" colname="col5" colwidth="18*"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MCL (<italic>n</italic> = 9)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CLL (<italic>n</italic> = 3)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">FL (<italic>n</italic> = 4)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">DLBCL (<italic>n</italic> = 4)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Mean GI<inf loc="post">50</inf>
                           <br/></br>at 24 h (μM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.6<br/></br>(range: 1.3–5.9)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.9<br/></br>(range: 5.3–6.8)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.7<br/></br>(range: 2.6–4.9)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.4<br/></br>(range: 4.3–6.9)</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Mean GI<inf loc="post">50</inf>
                           <br/></br>at 48 h (μM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.0<br/></br>(range: 2.2–3.6)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.9<br/></br>(range: 4.5–5.5)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.7<br/></br>(range: 1.4–4.4)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.0<br/></br>(range: 3.8–7.2)</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Original article</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-<ce:italic>d</ce:italic>]pyrimidin-7-(8<ce:italic>H</ce:italic>)-ones as BCR kinase inhibitors for B lymphoid malignancies</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1">
                  <ce:given-name>Raimon</ce:given-name>
                  <ce:surname>Puig de la Bellacasa</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0010">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au2">
                  <ce:given-name>Gaël</ce:given-name>
                  <ce:surname>Roué</ce:surname>
                  <ce:cross-ref refid="aff2" id="crosref0015">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au3">
                  <ce:given-name>Patricia</ce:given-name>
                  <ce:surname>Balsas</ce:surname>
                  <ce:cross-ref refid="aff2" id="crosref0020">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au4">
                  <ce:given-name>Patricia</ce:given-name>
                  <ce:surname>Pérez-Galán</ce:surname>
                  <ce:cross-ref refid="aff2" id="crosref0025">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au5" orcid="0000-0002-2720-9811">
                  <ce:given-name>Jordi</ce:given-name>
                  <ce:surname>Teixidó</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0030">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au6">
                  <ce:given-name>Dolors</ce:given-name>
                  <ce:surname>Colomer</ce:surname>
                  <ce:cross-ref refid="aff2" id="crosref0035">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="cor1" id="crosref0040">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au7" orcid="0000-0001-9409-2919">
                  <ce:given-name>José I.</ce:given-name>
                  <ce:surname>Borrell</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0045">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="cor1" id="crosref0050">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1">
                  <ce:label>a</ce:label>
                  <ce:textfn>Grup d'Enginyeria Molecular, Institut Químic de Sarrià, Universitat Ramon Llull, Via Augusta 390, E-08017 Barcelona, Spain</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Grup d'Enginyeria Molecular</sa:organization>
                     <sa:organization>Institut Químic de Sarrià</sa:organization>
                     <sa:organization>Universitat Ramon Llull</sa:organization>
                     <sa:address-line>Via Augusta 390</sa:address-line>
                     <sa:city>Barcelona</sa:city>
                     <sa:postal-code>E-08017</sa:postal-code>
                     <sa:country>Spain</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff2">
                  <ce:label>b</ce:label>
                  <ce:textfn>Institut d'Investigacions Mèdiques August Pi i Sunyer (IDIBAPS), Rosselló, 149-153, E-08036 Barcelona, Spain</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Institut d'Investigacions Mèdiques August Pi i Sunyer (IDIBAPS)</sa:organization>
                     <sa:address-line>Rosselló, 149-153</sa:address-line>
                     <sa:city>Barcelona</sa:city>
                     <sa:postal-code>E-08036</sa:postal-code>
                     <sa:country>Spain</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding authors.</ce:text>
               </ce:correspondence>
            </ce:author-group>
            <ce:date-received day="10" month="4" year="2014"/></ce:date-received>
            <ce:date-revised day="4" month="9" year="2014"/></ce:date-revised>
            <ce:date-accepted day="6" month="9" year="2014"/></ce:date-accepted>
            <ce:abstract xml:lang="en" id="abs0010" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">A new family of 4-aminopyrido[2,3-<ce:italic>d</ce:italic>]pyrimidines active against non-Hodgkin's lymphomas (NHLs) is described. Among these compounds, <ce:bold>19</ce:bold> inhibits the most upstream tyrosine kinases in the B cell receptor (BCR) signaling pathway which are involved in the mature B cell neoplasms. Thus, <ce:bold>19</ce:bold> showed antiproliferative activity at 24 h and 48 h against a panel of 20 NHLs cell lines with GI<ce:inf loc="post">50</ce:inf> ranging from 1.3 to 6.9 μM at 24 h, and 1.4–7.2 μM at 48 h, being this effect related to a significant (20–90%) inhibition of the phosphorylation of the BCR-related kinases Btk, Syk, and Lyn. Most importantly, <ce:bold>19</ce:bold> was able to induce a 63% reduction in Rec-1 cell proliferation, which was significantly greater than the 31% and 3% blockade of proliferation observed after cell treatment with R406, a Syk inhibitor, and ibrutinib, a Btk inhibitor, respectively. The computational blind docking and ligand binding within the pockets of Btk, Syk and Lyn kinases showed that compound <ce:bold>19</ce:bold> presents the same kind of interactions of described cocrystallized inhibitors.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:link locator="fx1"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords xml:lang="en" id="kwrds0010" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Non-Hodgkin's lymphomas</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>B-cell receptor</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Kinases</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Small molecule inhibitor</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>7-oxopyrido[2,3-<ce:italic>d</ce:italic>]pyrimidines</ce:text>
               </ce:keyword>
            </ce:keywords>
            <ce:keywords xml:lang="en" class="abr" id="kwrds0015" view="all">
               <ce:section-title id="sectitle0030">Abbreviations</ce:section-title>
               <ce:keyword id="kwrd0035">
                  <ce:text>Abl</ce:text>
                  <ce:keyword id="kwrd0040">
                     <ce:text>Abelson</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0045">
                  <ce:text>Bcl-2</ce:text>
                  <ce:keyword id="kwrd0050">
                     <ce:text>B-cell lymphoma 2</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0055">
                  <ce:text>BCR</ce:text>
                  <ce:keyword id="kwrd0060">
                     <ce:text>B-cell receptor</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0065">
                  <ce:text>Btk</ce:text>
                  <ce:keyword id="kwrd0070">
                     <ce:text>Bruton's tyrosine kinase</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0075">
                  <ce:text>CLL</ce:text>
                  <ce:keyword id="kwrd0080">
                     <ce:text>chronic lymphocytic leukemia</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0085">
                  <ce:text>DLBCL</ce:text>
                  <ce:keyword id="kwrd0090">
                     <ce:text>diffuse large B-cell lymphoma</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0095">
                  <ce:text>FDA</ce:text>
                  <ce:keyword id="kwrd0100">
                     <ce:text>food and drug administration</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0105">
                  <ce:text>FITC</ce:text>
                  <ce:keyword id="kwrd0110">
                     <ce:text>fluorescein isothiocyanate</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0115">
                  <ce:text>FL</ce:text>
                  <ce:keyword id="kwrd0120">
                     <ce:text>follicular lymphoma</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0125">
                  <ce:text>GI<ce:inf loc="post">50</ce:inf>
                  </ce:text>
                  <ce:keyword id="kwrd0130">
                     <ce:text>half growth inhibitory concentration</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0135">
                  <ce:text>MCL</ce:text>
                  <ce:keyword id="kwrd0140">
                     <ce:text>mantle cell lymphoma</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0145">
                  <ce:text>NHL</ce:text>
                  <ce:keyword id="kwrd0150">
                     <ce:text>Non-Hodgkin's lymphoma</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0155">
                  <ce:text>PBMC</ce:text>
                  <ce:keyword id="kwrd0160">
                     <ce:text>peripheral blood mononuclear cell</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0165">
                  <ce:text>PE</ce:text>
                  <ce:keyword id="kwrd0170">
                     <ce:text>phycoerythrin</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0175">
                  <ce:text>PI</ce:text>
                  <ce:keyword id="kwrd0180">
                     <ce:text>propidium iodide</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0185">
                  <ce:text>Syk</ce:text>
                  <ce:keyword id="kwrd0190">
                     <ce:text>spleen tyrosine kinase</ce:text>
                  </ce:keyword>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0035">Introduction</ce:section-title>
                  <ce:para id="p0035" view="all">Lymphoma is a malignancy of mature lymphocytes that manifests in secondary lymphoid organs and/or extranodal tissues. In the United States, lymphoma is the sixth most common form of cancer, affecting 22.5 per 100,000 people. Non-Hodgkin's lymphomas (NHLs) represent a heterogeneous group of malignancies arising from the lymphoid system. They represent the malignant counterpart of different steps of B-lymphocyte differentiation. Similar to other types of cancer, they are the result of a multistep accumulation of genetic aberrations that induce a selective growth advantage of the malignant clone <ce:cross-ref refid="bib1" id="crosref0055">[1]</ce:cross-ref>. The most common NHL subtypes are diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). DLBCL is the term applied to a constellation of different disorders with specific clinico-pathological features. The activated B-cell-like (ABC) and germinal center B-cell-like (GCB) subtypes of DLBCL were defined by their apparent derivation from different stages of B-cell differentiation and their differential response to chemotherapy. With current chemotherapy supplemented with Rituximab, the ABC-DLBCL subtype remains less curable than the GCB subtype <ce:cross-ref refid="bib2" id="crosref0060">[2]</ce:cross-ref>. FL is derived from a germinal center B cell and is characterized by the presence of t(14;18)(q32;q21) translocation that juxtaposes the <ce:italic>BCL2</ce:italic> gene and the IGH locus, leading to the overexpression of the anti-apoptotic protein Bcl-2 <ce:cross-ref refid="bib3" id="crosref0065">[3]</ce:cross-ref>. Mantle cell lymphoma (MCL) is one of the most difficult to treat subtypes of NHL. It is genetically characterized by the chromosomal translocation t(11;14)(q13;q32), which results in aberrant expression of cyclin D1. Additional chromosome alterations that target genes involved in molecular pathways, such as cell cycle control, DNA damage response, and cell survival pathways, are frequently found in MCL <ce:cross-ref refid="bib4" id="crosref0070">[4]</ce:cross-ref>. Chronic lymphocytic leukemia (CLL) is a leukemic form of NHLs that is one of the most frequent tumors in Western countries characterized by the proliferation and progressive accumulation of mature clonal B lymphocytes CD5+ in blood, bone marrow and lymphoid tissues <ce:cross-ref refid="bib5" id="crosref0075">[5]</ce:cross-ref>. In recent years, advances in NHL have produced information critical to our understanding of cell growth, proliferation and cell death.</ce:para>
                  <ce:para id="p0040" view="all">Although the standard of care for each type of NHL varies, most regimens use combinations of cytotoxic drugs along with immunotherapy. Generally, indolent lymphomas such as FL and CLL have less robust responses to immunochemotherapies than aggressive lymphomas such as DLBCL. However, many patients do not show a durable response to treatments and relapses are frequent in these patients. In the recent years, B cell receptor (BCR) signaling has emerged as a central oncogenic pathway that promotes growth and survival in various lymphoma types. Several kinases participate in the cascade of effectors downstream of the BCR that has been considered targets for a possible therapeutic intervention such as Lyn, Syk (spleen tyrosine kinase), and Btk (Bruton's tyrosine kinase) that might play an important role in the pathogenesis of NHLs. Recently, several inhibitors against these kinases have been reported to have a therapeutic potential for the treatment of these entities <ce:cross-ref refid="bib6" id="crosref0080">[6]</ce:cross-ref>.</ce:para>
                  <ce:para id="p0045" view="all">Lyn is a member of the SRC family kinases. Dasatinib (<ce:bold>1</ce:bold>) (<ce:cross-ref refid="fig8" id="crosref0085">Chart 1</ce:cross-ref>
                     <ce:float-anchor refid="fig8"/></ce:float-anchor>) is an oral multi-kinase inhibitor used to target the BCR-ABL fusion protein produced by the t(9;22) translocation in chronic myelogenous leukemia <ce:cross-ref refid="bib7" id="crosref0090">[7]</ce:cross-ref>. Dasatinib also efficiently targets SRC-family kinases and Btk <ce:cross-ref refid="bib8" id="crosref0095">[8]</ce:cross-ref>. A Phase II trial of dasatinib in CLL yielded a 20% objective response rate <ce:cross-ref refid="bib9" id="crosref0100">[9]</ce:cross-ref>. Syk is a non-receptor tyrosine kinase that is crucial to antigen-dependent BCR signaling and has also additional roles in several hematopoietic lineages that can be traced to its involvement in integrin and selectin signaling and in certain innate immune receptors. The first Syk inhibitor to enter clinical trials for lymphoma was fostamatinib (R788) (<ce:bold>2</ce:bold>), an orally available pro-drug version of the active R406 compound, which is an ATP-competitive inhibitor. In vitro kinase assays demonstrated that R406 can inhibit also Fms-like tyrosine kinase 3 (FLT3), KIT, lymphocyte cell-specific protein-tyrosine kinase (LCK), Janus kinase 1 (JAK1), JAK3, RET and the adenosine A3 receptor with similar potencies. Fostamatinib has completed Phase I and Phase II clinical trials examining its toxicity and efficacy in the context of autoimmune diseases and hematological malignancies. A Phase I/II clinical trial of fostamatinib in relapsed or refractory NHL indicated significant clinical activity. The study reported objective response rates of 55% in CLL, 24% in DLBCL, 11% in MCL and 10% in FL <ce:cross-ref refid="bib10" id="crosref0105">[10]</ce:cross-ref>. Btk is a kinase essential for antigen-stimulated BCR signaling. Ibrutinib (<ce:bold>3</ce:bold>) is a Btk inhibitor, whose initial phase 1 dose escalation study reported responses in 60% of patients with various B-cell malignancies <ce:cross-ref refid="bib11" id="crosref0110">[11]</ce:cross-ref>. Two recent phase 1b-2 clinical trials further demonstrated a durable single-agent activity and favorable toxicity profile of this agent in 85 relapsed CLL and 111 relapsed/refractory MCL patients, with response rates closed to 70% <ce:cross-refs refid="bib12 bib13" id="crosrefs0010">[12,13]</ce:cross-refs>.</ce:para>
                  <ce:para id="p0050" view="all">It becomes evident that targeting one or more of Lyn, Syk, and Btk kinases with small molecular inhibitors seems to be a promising strategy in the treatment of these mature B cell neoplasms.</ce:para>
                  <ce:para id="p0055" view="all">Functionalized pyrido[2,3-<ce:italic>d</ce:italic>]pyrimidine derivatives comprise a privileged scaffold for pharmacologically active compounds with well-known activity as tyrosine kinase inhibitors <ce:cross-ref refid="bib14" id="crosref0115">[14]</ce:cross-ref>. Usually pyrido[2,3-<ce:italic>d</ce:italic>]pyrimidines <ce:bold>4</ce:bold> are obtained through a multistep strategy in which the pyridine ring is constructed by condensation of a nitrile <ce:bold>5</ce:bold> (bearing the desired substituent R<ce:sup loc="post">1</ce:sup>) onto a preformed pyrimidine aldehyde <ce:bold>6</ce:bold> bearing substituent R<ce:sup loc="post">5</ce:sup> and a methylthio group which can later be substituted by NH<ce:inf loc="post">2</ce:inf>R<ce:sup loc="post">4</ce:sup> substituent using an amine <ce:bold>7</ce:bold> (<ce:cross-ref refid="fig1" id="crosref0120">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>).</ce:para>
                  <ce:para id="p0060" view="all">In this context, our group has a broad experience in the synthesis of 4-amino-5,6-dihydropyrido[2,3-<ce:italic>d</ce:italic>]pyrimidin-7-(8<ce:italic>H</ce:italic>)-ones (<ce:bold>12</ce:bold>) (<ce:cross-ref refid="sch1" id="crosref0125">Scheme 1</ce:cross-ref>
                     <ce:float-anchor refid="sch1"/></ce:float-anchor>) from α,β-unsaturated esters (<ce:bold>8</ce:bold>). Thus, 2-methoxy-6-oxo-1,4,5,6-tetrahydropyridin-3-carbonitriles (<ce:bold>10</ce:bold>) are obtained by reaction of an α,β-unsaturated ester (<ce:bold>8</ce:bold>) and malonitrile (<ce:bold>9</ce:bold>) in NaOMe/MeOH <ce:cross-ref refid="bib15" id="crosref0130">[15]</ce:cross-ref>. Treatment of pyridones <ce:bold>10</ce:bold> with guanidine systems (<ce:bold>11</ce:bold>, R<ce:sup loc="post">4</ce:sup> = H, alkyl, aryl) affords 4-amino-pyrido[2,3-<ce:italic>d</ce:italic>]pyrimidines (<ce:bold>12</ce:bold>, R<ce:sup loc="post">4</ce:sup> = H, alkyl, aryl) <ce:cross-ref refid="bib16" id="crosref0135">[16]</ce:cross-ref>.</ce:para>
                  <ce:para id="p0065" view="all">More recently, we have developed protocols for the dehydrogenation of 5,6-dihydropyrido[2,3-<ce:italic>d</ce:italic>]pyrimidin-7(8<ce:italic>H</ce:italic>)-ones <ce:bold>12</ce:bold> to pyrido[2,3-<ce:italic>d</ce:italic>]pyrimidin-7(8<ce:italic>H</ce:italic>)-ones <ce:bold>14</ce:bold> 
                     <ce:cross-ref refid="bib17" id="crosref0140">[17]</ce:cross-ref> and a methodology for the synthesis of 2-arylamino substituted 4-amino-5,6-dihydropyrido[2,3-<ce:italic>d</ce:italic>]pyrimidin-7(8<ce:italic>H</ce:italic>)-ones (<ce:bold>12</ce:bold>, R<ce:sup loc="post">4</ce:sup> = aryl) via the corresponding 3-aryl substituted pyridopyrimidines <ce:bold>13</ce:bold>, formed upon treatment of pyridones <ce:bold>10</ce:bold> with an arylsubstituted guanidine <ce:bold>11</ce:bold> in dioxane, which underwent the Dimroth rearrangement to the desired 4-aminopyridopyrimidines (<ce:bold>12</ce:bold>, R<ce:sup loc="post">4</ce:sup> = aryl) with NaOMe/MeOH. The overall yields of such two-step protocol are in general higher than the reaction between pyridones <ce:bold>10</ce:bold> and an arylsubstituted guanidine <ce:bold>11</ce:bold> (<ce:cross-ref refid="sch1" id="crosref0145">Scheme 1</ce:cross-ref>) <ce:cross-ref refid="bib18" id="crosref0150">[18]</ce:cross-ref>.</ce:para>
                  <ce:para id="p0070" view="all">The present paper deals with the use of such methodology for the synthesis of 4-amino-7-aryl-2-arylaminopyrido[2,3-<ce:italic>d</ce:italic>]pyrimidin-7-(8<ce:italic>H</ce:italic>)-ones active against NHLs.</ce:para>
               </ce:section>
               <ce:section id="sec2" role="results" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0040">Results and discussion</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0045">Chemistry</ce:section-title>
                     <ce:para id="p0075" view="all">As a part of our ongoing program to develop new therapeutic agents based on tyrosine kinase inhibitors, we synthesized a library of compounds of general structures <ce:bold>12</ce:bold>, <ce:bold>13</ce:bold> and <ce:bold>14</ce:bold> by varying the nature of substituents R<ce:sup loc="post">1</ce:sup> (H, alkyl, aryl, heteroaryl) and R<ce:sup loc="post">4</ce:sup> (H, alkyl, aryl, heteroaryl). Among this compounds, <ce:bold>12a</ce:bold> (R<ce:sup loc="post">1</ce:sup> = C<ce:inf loc="post">6</ce:inf>H<ce:inf loc="post">3</ce:inf>-2,6-Cl<ce:inf loc="post">2</ce:inf>, R<ce:sup loc="post">4</ce:sup> = Ph) (<ce:cross-ref refid="fig9" id="crosref0155">Chart 2</ce:cross-ref>
                        <ce:float-anchor refid="fig9"/></ce:float-anchor>) <ce:cross-ref refid="bib18" id="crosref0160">[18]</ce:cross-ref>, obtained starting from methyl 2-(2,6-dichlorophenyl)acrylate (<ce:bold>8a</ce:bold>, R<ce:sup loc="post">1</ce:sup> = C<ce:inf loc="post">6</ce:inf>H<ce:inf loc="post">3</ce:inf>-2,6-Cl<ce:inf loc="post">2</ce:inf>) and phenylguanidine carbonate (<ce:bold>11a</ce:bold>, R<ce:sup loc="post">4</ce:sup> = Ph) and which precisely contains the 2,6-dichlorophenyl substituent present in several biologically active pyrido[2,3-<ce:italic>d</ce:italic>]pyrimidines previously reported <ce:cross-refs refid="bib19 bib20" id="crosrefs0015">[19,20]</ce:cross-refs>, showed a promising biological activity against two MCL cell lines. Thus, the dose and time response of compound <ce:bold>12a</ce:bold> was determined against HBL-2 and Rec-1. The respective GI<ce:inf loc="post">50</ce:inf> were: HBL-2, GI<ce:inf loc="post">50</ce:inf>(24 h) = 12.0 ± 0.05 μM and GI<ce:inf loc="post">50</ce:inf>(48 h) = 5.7 ± 0.01 μM; Rec-1, GI<ce:inf loc="post">50</ce:inf>(24 h) > 100 μM and an GI<ce:inf loc="post">50</ce:inf>(48 h) = 52.3 ± 0.03 μM, being GI<ce:inf loc="post">50</ce:inf> the dose at which cell growth is inhibited by 50%.</ce:para>
                     <ce:para id="p0080" view="all">Such results impelled us to construct a sublibrary around the structure of compound <ce:bold>12a</ce:bold>. Consequently, the lactam nitrogen of <ce:bold>12a</ce:bold> was methylated (MeI, 60% NaH, anhydrous DMSO, rt) to afford <ce:bold>15</ce:bold> (<ce:cross-ref refid="fig9" id="crosref0165">Chart 2</ce:cross-ref>). On the other hand, <ce:bold>12a</ce:bold> was aromatized (60% NaH, anhydrous DMSO, 100 °C, 4 h) to give <ce:bold>14a</ce:bold> which was further methylated in the lactam nitrogen (MeI, 60% NaH, anhydrous DMSO, rt) to yield <ce:bold>16</ce:bold> (<ce:cross-ref refid="fig9" id="crosref0170">Chart 2</ce:cross-ref>). Furthermore, the lactam carbonyl group of <ce:bold>12a</ce:bold> was reduced (BH<ce:inf loc="post">3</ce:inf>·THF, 50 °C, 3d) to afford <ce:bold>17</ce:bold> (<ce:cross-ref refid="fig9" id="crosref0175">Chart 2</ce:cross-ref>). Finally, we obtained the 2,4-diaminopyrido[2,3-<ce:italic>d</ce:italic>]pyrimidine <ce:bold>12b</ce:bold> (R<ce:sup loc="post">1</ce:sup> = C<ce:inf loc="post">6</ce:inf>H<ce:inf loc="post">3</ce:inf>-2,6-Cl<ce:inf loc="post">2</ce:inf>, R<ce:sup loc="post">4</ce:sup> = H) (<ce:cross-ref refid="fig9" id="crosref0180">Chart 2</ce:cross-ref>) by using guanidine carbonate (<ce:bold>11b</ce:bold>) in the cyclization step (<ce:cross-ref refid="sch1" id="crosref0185">Scheme 1</ce:cross-ref>).</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0050">Biological evaluation of synthesized compounds</ce:section-title>
                     <ce:para id="p0085" view="all">Subsequently, the dose and time responses of these compounds were determined against the same MCL cell lines: HBL-2 and Rec-1. The resulting curves are depicted in <ce:cross-ref refid="fig2" id="crosref0190">Fig. 2</ce:cross-ref>
                        <ce:float-anchor refid="fig2"/></ce:float-anchor> and the corresponding GI<ce:inf loc="post">50</ce:inf>(24 h) and GI<ce:inf loc="post">50</ce:inf>(48 h) are summarized in <ce:cross-ref refid="tbl1" id="crosref0195">Table 1</ce:cross-ref>
                        <ce:float-anchor refid="tbl1"/></ce:float-anchor>.</ce:para>
                     <ce:para id="p0090" view="all">On the basis of these results, we selected compound <ce:bold>16</ce:bold> for further development due to its good cytostatic activity both at 24 h and 48 h. Moreover, <ce:bold>16</ce:bold> showed a high potency against the bortezomib-resistant MCL cell line JBR <ce:cross-ref refid="bib21" id="crosref0200">[21]</ce:cross-ref> affording an GI<ce:inf loc="post">50</ce:inf>(24 h) = 3.1 ± 0.01 μM and an GI<ce:inf loc="post">50</ce:inf>(48 h) = 0.9 ± 0.04 μM.</ce:para>
                     <ce:para id="p0095" view="all">Specificity of <ce:bold>16</ce:bold> was evaluated by treating for 24 h primary peripheral blood mononuclear cells (PBMCs) isolated from 2 healthy donors, with increasing doses of the compound. <ce:cross-ref refid="fig3" id="crosref0205">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="fig3"/></ce:float-anchor> shows that in the range of doses previously shown to be highly active in MCL cell lines, only 3–15% of normal cells underwent apoptotic cell death at this time point, thus demonstrating the specificity of <ce:bold>16</ce:bold> toward tumor cells.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0055">Development and biological evaluation of a water soluble analogue of compound <ce:bold>16</ce:bold>
                     </ce:section-title>
                     <ce:para id="p0100" view="all">One of the main issues that usually precludes the use of pyrido[2,3-<ce:italic>d</ce:italic>]pyrimidines as drugs is their limited solubility in water, which is also the case of compound <ce:bold>16</ce:bold> (less than 1 mg/L) precluding its potential use as a drug candidate. A typical way to overcome such problem is to introduce a substituent containing a tertiary amine from which a water soluble salt could be obtained. Of course such modification must be carried out without affecting the biological activity of the parent compound. In referable pyrido[2,3-<ce:italic>d</ce:italic>]pyrimidines the aforementioned substituent was introduced in <ce:italic>para</ce:italic> position of the 2-phenylamino substituent <ce:cross-refs refid="bib19 bib20" id="crosrefs0020">[19,20]</ce:cross-refs>, consequently we decided to functionalize the same position. To introduce such tertiary amine we first brominate the <ce:italic>para</ce:italic> position of the 2-phenylamino substituent present in <ce:bold>16</ce:bold> by using 2 M Br<ce:inf loc="post">2</ce:inf> in acetic acid for 2 h at rt to afford compound <ce:bold>18</ce:bold> (<ce:cross-ref refid="fig10" id="crosref0210">Chart 3</ce:cross-ref>
                        <ce:float-anchor refid="fig10"/></ce:float-anchor>). The subsequent substitution of the bromine atom was carried out using Ullman reaction conditions. Thus, compound <ce:bold>19</ce:bold> was obtained in 69% yield by treating <ce:bold>18</ce:bold> with 1-methylpiperazine in DMSO in the presence of <ce:small-caps>l</ce:small-caps>-proline, copper(I) iodide, and K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> under microwave irradiation for 16 h at 80 °C. Compound <ce:bold>20</ce:bold> (<ce:cross-ref refid="fig10" id="crosref0215">Chart 3</ce:cross-ref>) was obtained in 77% yield upon treatment with 4-(aminoethyl)morpholine under the same reaction conditions. Finally, <ce:bold>21</ce:bold> was formed (18%) by using 4-(2-hydroxyethyl)morpholine as solvent in the presence of copper(I) iodide and Cs<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> under microwave irradiation for 18 h at 180 °C (<ce:cross-ref refid="fig10" id="crosref0220">Chart 3</ce:cross-ref>).</ce:para>
                     <ce:para id="p0105" view="all">Compounds <ce:bold>19</ce:bold>, <ce:bold>20</ce:bold>, and <ce:bold>21</ce:bold> were evaluated against MCL cell lines Rec-1 and HBL-2 and <ce:bold>19</ce:bold> was selected due to its lower GI<ce:inf loc="post">50</ce:inf> values (HBL-2: IC<ce:inf loc="post">50</ce:inf>(24 h) = 4.9 ± 0.01 μM and GI<ce:inf loc="post">50</ce:inf>(48 h) = 2.6 ± 0.02 μM; Rec-1: GI<ce:inf loc="post">50</ce:inf>(24 h) = 3.2 ± 0.01 μM and GI<ce:inf loc="post">50</ce:inf>(48 h) = 3.0 ± 0.04 μM) which are in the same order of those obtained for <ce:bold>12a</ce:bold>. Furthermore, in order to envisage the kinases targeted by these compounds, the kinase inhibition profile of <ce:bold>19</ce:bold>, <ce:bold>20</ce:bold>, and <ce:bold>21</ce:bold> was evaluated at Proqinase (<ce:inter-ref xlink:href="http://www.proqinase.com" id="intref0010" xlink:type="simple">http://www.proqinase.com</ce:inter-ref>) by measuring residual activity values (%) at a concentration of 10 μM of the test compound in front of kinases involved in NHLs. The results obtained (<ce:cross-ref refid="tbl2" id="crosref0225">Table 2</ce:cross-ref>
                        <ce:float-anchor refid="tbl2"/></ce:float-anchor>) indicate that these compounds target Btk, Lyn, and Syk aa1-635 kinases, being compound <ce:bold>19</ce:bold> the strongest inhibitor. So, <ce:bold>19</ce:bold> is inhibiting the most upstream tyrosine kinases involved in the BCR signaling.</ce:para>
                     <ce:para id="p0110" view="all">To further assess the inhibitory effect of <ce:bold>19</ce:bold> on the activity of BCR kinases, the representative MCL cell line Rec-1 was exposed for 6 h to 0.1, 1 or 5 μM doses of the compound and phospho-Syk, phospho-Lyn and phospho-Btk were analyzed by western blotting or flow cytometry using phospho-specific antibodies. <ce:cross-ref refid="fig4" id="crosref0230">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="fig4"/></ce:float-anchor>(A) shows that the compound inhibited Syk and Lyn phosphorylation as soon as 6 h of treatment, being this inhibition dose-dependent as it is shown at 5 μM. Similarly, <ce:cross-ref refid="fig4" id="crosref0235">Fig. 4</ce:cross-ref>(B) shows that compound <ce:bold>19</ce:bold> induced in Rec-1 cells a 10% and 40% downregulation of phospho-Btk when used at 1 μM and 5 μM dose, based on the respective dose-related decrease of the mean fluorescence intensity ratios.</ce:para>
                     <ce:para id="p0115" view="all">The antitumoral activity of compound <ce:bold>19</ce:bold> was then assessed by MTT assay against a panel of 20 human NHL cell lines, being 9 out of them of the MCL subtype (Rec-1, HBL-2, UPN-1, Jeko-1, JVM-2, Maver-1, Mino, Granta-519, and Z-138), 3 of the CLL subtype (MEC-2, JVM-13, and MEC-1), 4 of the FL subtype (DoHH-2, WSU-NHL, WSU-FSCCL, and SC-1), and 4 of the DLBCL subtype (OCI-LY8, SUDHL-8, U-2932, and SUDHL-16). Cells were exposed for 24 h or 48 h to increasing doses of the compound and GI<ce:inf loc="post">50</ce:inf> values were calculated and represented on <ce:cross-ref refid="fig5" id="crosref0240">Fig. 5</ce:cross-ref>
                        <ce:float-anchor refid="fig5"/></ce:float-anchor>. Compound <ce:bold>19</ce:bold> showed comparable antiproliferative activity at 24 h and 48 h in the tested cell lines, with GI<ce:inf loc="post">50</ce:inf> ranging from 1.3 to 6.9 μM (mean = 4.3) at 24 h, and from 1.4 to 7.2 μM (mean = 3.6) at 48 h. <ce:cross-ref refid="tbl3" id="crosref0245">Table 3</ce:cross-ref>
                        <ce:float-anchor refid="tbl3"/></ce:float-anchor> shows the GI<ce:inf loc="post">50</ce:inf> values in each entity.</ce:para>
                     <ce:para id="p0120" view="all">Finally, we compared the anti-tumor activity of compound <ce:bold>19</ce:bold> with the first-in-class Btk inhibitor ibrutinib and the small-molecule Syk inhibitor R406, the active metabolite of fostamatinib. Rec-1 cells were exposed to a 2.5 μM dose of each compound and phosphorylation levels of Lyn, Syk and Btk, and cell proliferation were analyzed by western blotting, after 6 h of incubation. Proliferation was assessed by the MTT assay using the same doses after 24 h of incubation with the respective drug. <ce:cross-ref refid="fig6" id="crosref0250">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor>(A) shows that at the dose tested, both compound 19 and R406 led to an almost complete inhibition of the three BCR-related kinases, while, as expected, ibrutinib mostly counteracted Btk phosphorylation and only slightly affected Lyn phosphorylation at Tyr396. Most importantly, compound <ce:bold>19</ce:bold> was able to induce a 63% reduction in Rec-1 cell proliferation, which was significantly greater than the 31% and 3% blockade of proliferation observed after cell treatment with R406 (<ce:italic>p</ce:italic> = 0.0083) and ibrutinib (<ce:italic>p</ce:italic> = 0.0006), respectively (<ce:cross-ref refid="fig6" id="crosref0255">Fig. 6</ce:cross-ref>(B)).</ce:para>
                     <ce:para id="p0125" view="all">Altogether, these results indicate that compound <ce:bold>19</ce:bold> exerts a dose-dependent antitumoral activity in MCL, CLL, FL, and DLBCL cells, in the micromolar range, and that this effect is related to the inhibition of the phosphorylation of BCR-related kinases. Moreover, this activity appears to be selective for tumoral B cells and is significantly enhanced when compared to the BCR-interfering drugs used in the clinical for the treatment of NHLs. As for the solubility in water, <ce:bold>19</ce:bold> was transformed in the corresponding dimesylate salt <ce:bold>19</ce:bold>·(<ce:bold>MsOH</ce:bold>)<ce:inf loc="post">
                           <ce:bold>2</ce:bold>
                        </ce:inf>, upon treatment with 2 equiv of methanesulfonic acid in acetone (87% yield), which presents a water solubility of 10 mg/mL.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.4" view="all">
                     <ce:label>2.4</ce:label>
                     <ce:section-title id="sectitle0060">Computational blind docking studies of compound <ce:bold>19</ce:bold>
                     </ce:section-title>
                     <ce:para id="p0130" view="all">Finally, computational blind docking and ligand binding of compound <ce:bold>19</ce:bold> within the binding pockets of Btk, Syk, and Lyn kinases was carried out using the Btk, Syk, and Lyn kinase domains cocrystallized with a pyridopyrimidine <ce:cross-ref refid="bib22" id="crosref0260">[22]</ce:cross-ref>, a different pyridopyrimdine <ce:cross-ref refid="bib23" id="crosref0265">[23]</ce:cross-ref>, and dasatinib <ce:cross-ref refid="bib24" id="crosref0270">[24]</ce:cross-ref>, respectively. The results from docking analyses showed that compound <ce:bold>19</ce:bold> perfectly fits in the three kinase domains as depicted in <ce:cross-ref refid="fig7" id="crosref0275">Fig. 7</ce:cross-ref>
                        <ce:float-anchor refid="fig7"/></ce:float-anchor>.</ce:para>
                     <ce:para id="p0135" view="all">Thus, in the case of Btk (<ce:cross-ref refid="fig7" id="crosref0280">Fig. 7</ce:cross-ref>(A)) there are two hydrogen bridges between N2 and NH of Met477 (3.22 Å) and NHPh and O (sp<ce:sup loc="post">2</ce:sup>) of Met477 (2.91 Å), the same kind of interactions showed by the pyridopyrimidine complexed with the Btk kinase domain (depicted in yellow).</ce:para>
                     <ce:para id="p0140" view="all">On the other hand, in the case of Syk (<ce:cross-ref refid="fig7" id="crosref0285">Fig. 7</ce:cross-ref>(B)) there are also two hydrogen bridges between N2 and NH of Ala451 (3.22 Å) and NHPh and O (sp<ce:sup loc="post">2</ce:sup>) of Ala451 (2.73 Å). This lower energy interaction also has the same interactions showed by the pyridopyrimidine cocrystallized with the Syk kinase (depicted in green).</ce:para>
                     <ce:para id="p0145" view="all">Finally, in the case of Lyn (<ce:cross-ref refid="fig7" id="crosref0290">Fig. 7</ce:cross-ref>(C)) two hydrogen bridges are formed between N2 and NH of Met322 (3.32 Å) and NHPh and O (sp<ce:sup loc="post">2</ce:sup>) of Met322 (2.80 Å). Once more this interaction mimics the interaction showed by Dasatinib in the Lyn kinase domain (depicted in purple).</ce:para>
                     <ce:para id="p0150" view="all">Consequently, the docking studies clearly demonstrate that compound <ce:bold>19</ce:bold> is capable of presenting the same kind of interactions than other inhibitors of the Btk, Syk and Lyn kinase domains, sitting in a very similar way in the pockets of such kinases and overlapping with the conformations showed by the cocrystallized inhibitors <ce:cross-refs refid="bib22 bib23 bib24" id="crosrefs0025">[22–24]</ce:cross-refs>. Such computational behavior is in agreement with paninhibitor characteristics of compound <ce:bold>19</ce:bold> described above.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0065">Conclusions</ce:section-title>
                  <ce:para id="p0155" view="all">We obtained a new family of 4-aminopyrido[2,3-<ce:italic>d</ce:italic>]pyrimidnes active against NHLs starting from the previously described 4-amino-6-(2,6-dichlorophenyl)-5,6-dihydro-2-(phenylamino)pyrido[2,3-<ce:italic>d</ce:italic>]pyrimidin-7(8<ce:italic>H</ce:italic>)-one (<ce:bold>12a</ce:bold>) <ce:cross-ref refid="bib18" id="crosref0295">[18]</ce:cross-ref> which was aromatized to <ce:bold>14a</ce:bold>, methylated in the lactam nitrogen to afford <ce:bold>16</ce:bold>, brominated in the <ce:italic>para</ce:italic> position of the 2-phenylamino substituent to yield <ce:bold>18</ce:bold> whose bromine atom was subsequently substituted using the Ullman protocol to give compounds <ce:bold>19</ce:bold>, <ce:bold>20</ce:bold>, and <ce:bold>21</ce:bold> presenting a tertiary amine in such later substituent <ce:cross-ref refid="bib25" id="crosref0300">[25]</ce:cross-ref>.</ce:para>
                  <ce:para id="p0160" view="all">Among these compounds, <ce:bold>19</ce:bold> inhibits the most upstream tyrosine kinases in the BCR pathway which are involved in NHLs, in particular in the mature B cell neoplasms CLL, MCL, FL and DLBCL. Thus, compound <ce:bold>19</ce:bold> showed comparable antiproliferative activity at 24 h and 48 h against a panel of 20 NHLs cell lines (9 MCL cell lines, 3 CLL cell lines, 4 FL cell lines, and 4 DLBCL cell lines), with GI<ce:inf loc="post">50</ce:inf> ranging from 1.3 to 6.9 μM (mean = 4.3) at 24 h, and from 1.4 to 7.2 μM (mean = 3.6) at 48 h.</ce:para>
                  <ce:para id="p0165" view="all">The computational blind docking and ligand binding within the binding pockets of Btk, Syk, and Lyn kinases showed that compound <ce:bold>19</ce:bold> presents the same kind of interactions of cocrystallized inhibitors of the Btk, Syk and Lyn kinase domains overlapping with the conformations showed by such inhibitors.</ce:para>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0070">Experimental</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0075">Synthesis and characterization of compounds</ce:section-title>
                     <ce:section id="sec4.1.1" view="all">
                        <ce:label>4.1.1</ce:label>
                        <ce:section-title id="sectitle0080">General</ce:section-title>
                        <ce:para id="p0170" view="all">All solvents and chemicals were reagent grade. Unless otherwise mentioned, all solvents and chemicals were purchased from commercial vendors (Fluka, Aldrich, ABCR and ACROS Organics) and used without purification. Compound <ce:bold>12a</ce:bold> was prepared as previously described <ce:cross-ref refid="bib18" id="crosref0305">[18]</ce:cross-ref>. <ce:sup loc="pre">1</ce:sup>H and <ce:sup loc="pre">13</ce:sup>C NMR spectra were recorded on a Varian 400-MR spectrometer that was operating at a field strength of 400 and 100.6 MHz, respectively. Chemical shifts were reported in parts per million (<ce:italic>δ</ce:italic>) and coupling constants (<ce:italic>J</ce:italic>) were in Hz by using, in the case of <ce:sup loc="pre">1</ce:sup>H NMR spectroscopy, tetramethylsilane (TMS) as an internal standard, and in the case of <ce:sup loc="pre">13</ce:sup>C NMR spectroscopy, solvent residual peak was taken as reference: CDCl<ce:inf loc="post">3</ce:inf> at 77.0 ppm, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf> at 39.5 ppm. Standard and peak multiplicities are designed as follows: s, singlet; d, doublet; dd, doublet of doublets; dt, doublet of triplets t, triplet; br, broad signal. IR spectra were recorded in a Thermo Scientific Nicolet iS10 FTIR spectrophotometer with Smart iTr. Wavenumbers (<ce:italic>ν</ce:italic>) are expressed in cm<ce:sup loc="post">−1</ce:sup>. MS data (<ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> (%), EI, 70 eV) were obtained by using an Agilent Technologies 5975 spectrometer and a Hewlett Packard HP5988A quadrupole mass spectrometer operating in electronic ionization (EI) mode at 70 eV and at 4 kV accelerating potential, or a Bruker Biotoff II spectrometer operating in electrospray ionization (ESI) mode with a Time of Flight (TOF) detector or on a VG AutoSpec (Micromass Instruments) Triosector EBE spectrometer operating in Fast Atom Bombardment (FAB) mode. HRMS data were obtained by using a VG AutoSpec (Micromass Instruments) Trisector EBE high resolution spectrometer (EI or FAB mode), a Bruker Biotof II mass spectrometer (ESI TOF mode). Elemental microanalyses were obtained on a EuroVector Instruments Euro EA elemental analyzer. The melting points were determined with a Büchi-Tottoli 530 capillary apparatus and are uncorrected. Automatic flash chromatography was performed in an Isco Combiflash medium pressure liquid chromatograph with Redi<ce:italic>Sep</ce:italic>
                           <ce:sup loc="post">®</ce:sup> silica gel columns (35–70 μm) using a suitable mixture of solvents as eluent. Microwave irradiation experiments were carried out in an Initiator™ (Biotage) microwave apparatus, operating at a frequency of 2.45 GHz with continuous irradiation power from 0 to 400 W. Reactions were carried out in 0.5, 2.5, 5, and 20 mL glass tubes, sealed with aluminum/Teflon crimp tops, which can be exposed up to 250 °C and 20 bar internal pressure. Temperature was measured with an IR sensor on the outer surface of the process vial. After the irradiation period, the reaction vessel was cooled rapidly to 50 °C by air jet cooling.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.2" view="all">
                        <ce:label>4.1.2</ce:label>
                        <ce:section-title id="sectitle0085">4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (<ce:bold>14a</ce:bold>)</ce:section-title>
                        <ce:para id="p0175" view="all">A mixture of 200.1 mg (0.5 mmol) of 4-amino-6-(2,6-dichlorophenyl)-5,6-dihydro-2-(phenylamino)pyrido[2,3-<ce:italic>d</ce:italic>]pyrimidin-7(8<ce:italic>H</ce:italic>)-one (<ce:bold>12a</ce:bold>) <ce:cross-ref refid="bib18" id="crosref0310">[18]</ce:cross-ref> and 60.0 mg (1.5 mmol) of sodium hydride (NaH) (60% dispersion in mineral oil) in 5 mL of anhydrous DMSO was heated for 4 h at 100 °C protected from moisture. The resulting solution was cooled, water (300 mL) was added and the resulting solution was neutralized with AcOH. The resulting precipitate was filtered, washed with EtOH and EtOEt and dried <ce:italic>in vacuo</ce:italic> over phosphorus pentoxide to afford 173.3 mg (0.44 mmol, 87%) of <ce:bold>14a</ce:bold> as a slightly brownish solid. m.p. > 270 °C.</ce:para>
                        <ce:para id="p0180" view="all">
                           <ce:sup loc="pre">1</ce:sup>H NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> (ppm) 11.85 (br s, 1H), 9.26 (br s, 1H), 8.04 (s, 1H), 7.88 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 2H), 7.60–7.52 (m, 2H), 7.42 (dd, <ce:italic>J</ce:italic> = 8.7, 7.5 Hz, 1H), 7.29 (br s, 2H), 7.27–7.18 (m, 2H), 6.92 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 1H). <ce:sup loc="pre">13</ce:sup>C NMR (100.6 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> (ppm) 161.3, 161.1, 159.5, 156.1, 140.6, 135.5, 135.4, 135.0, 130.3, 128.3, 128.0, 121.6, 121.4, 119.5, 91.3. IR (KBr) <ce:italic>ν</ce:italic> (cm<ce:sup loc="post">−1</ce:sup>): 3344, 3213, 2957, 1615, 1595, 1564, 1530, 1500, 1448, 1308, 1261, 799, 587. MS (FAB) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> (%): 397.9 (100) [M+H]<ce:sup loc="post">+</ce:sup>, 361.9 (12). HRMS (FAB) calcd for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">14</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:sup loc="post">35</ce:sup>Cl<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup>: 398.0575; found: 398.0569. Anal. calculated for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">13</ce:inf>Cl<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">5</ce:inf>O: C 57.30, H 3.29, N 17.59; found: C 57.48, H 3.35, N 17.51.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.3" view="all">
                        <ce:label>4.1.3</ce:label>
                        <ce:section-title id="sectitle0090">4-Amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (<ce:bold>16</ce:bold>)</ce:section-title>
                        <ce:para id="p0185" view="all">28.0 mg (0.7 mmol) of sodium hydride (NaH) (60% dispersion in mineral oil) were added to a solution of 280.2 mg (0.7 mmol) of <ce:bold>14a</ce:bold> in 10 mL of anhydrous DMSO, and the mixture was stirred for 1 h at rt under nitrogen atmosphere. After this period, 43.8 μL (0.7 mmol) of methyl iodide were added dropwise and the resulting mixture was stirred overnight at rt. The reaction was quenched by addition of 300 mL of water and the resulting precipitate was filtered, washed with water and dried <ce:italic>in vacuo</ce:italic> over phosphorus pentoxide to afford 275.7 mg (0.67 mmol, 96%) of <ce:bold>16</ce:bold> as a slightly brownish solid. m.p. = 265–267 °C.</ce:para>
                        <ce:para id="p0190" view="all">
                           <ce:sup loc="pre">1</ce:sup>H NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> (ppm) 9.41 (br s, 1H), 8.09 (s, 1H), 7.82 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.56 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 7.42 (t, <ce:italic>J</ce:italic> = 7.6 Hz, 1H), 7.38 (br s, 2H), 7.28 (t, <ce:italic>J</ce:italic> = 7.7 Hz, 2H), 6.95 (t, <ce:italic>J</ce:italic> = 7.3 Hz, 1H), 3.59 (s, 3H). <ce:sup loc="pre">13</ce:sup>C NMR (100.6 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> (ppm) 161.7, 160.5, 159.07, 156.1, 140.4, 135.4, 135.3, 134.0, 130.3, 128.4, 128.0, 121.7, 120.1, 119.6, 91.6, 28.4. IR (KBr) <ce:italic>ν</ce:italic> (cm<ce:sup loc="post">−1</ce:sup>): 3335, 2924, 1631, 1575, 1521, 1497, 1469, 1448, 1341, 1308, 1194, 1010, 800. MS (FAB) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> (%): 412.0 (100) [M+H]<ce:sup loc="post">+</ce:sup>, 376.0 (31). HRMS (FAB) calcd for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">16</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:sup loc="post">35</ce:sup>Cl<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup>: 412.0732; found: 412.0726. Anal. calculated for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">15</ce:inf>Cl<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">5</ce:inf>O: C 58.27, H 3.67, N 16.99; found: C 58.53, H 3.69, N 17.07.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.4" view="all">
                        <ce:label>4.1.4</ce:label>
                        <ce:section-title id="sectitle0095">4-Amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-5,6-dihydropyrido[2,3-d]pyrimidin-7(8H)-one (<ce:bold>15</ce:bold>)</ce:section-title>
                        <ce:para id="p0195" view="all">28.0 mg (0.7 mmol) of sodium hydride (NaH) (60% dispersion in mineral oil) were added to a solution of 280.2 mg (0.7 mmol) of <ce:bold>12a</ce:bold> in 10 mL of anhydrous DMSO, and the resulting mixture was stirred for 1 h hour at rt under nitrogen atmosphere. After this period, 43.8 μL (0.7 mmol) of methyl iodide were added dropwise and then resulting solution was stirred overnight at rt. The reaction was quenched by addition of 300 mL of water and the resulting precipitate was filtered, washed with water and dried <ce:italic>in vacuo</ce:italic> over phosphorus pentoxide to afford 289.3 mg (0.7 mmol, 100%) of <ce:bold>15</ce:bold> as a white solid. m.p. = 202–205 °C.</ce:para>
                        <ce:para id="p0200" view="all">
                           <ce:sup loc="pre">1</ce:sup>H NMR (400 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> (ppm): 7.60 (dd, <ce:italic>J</ce:italic> = 8.7, 1.0 Hz, 2H), 7.36 (m, 2H), 7.32 (m, 2H) 7.20 (t, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 7.01 (t, <ce:italic>J</ce:italic> = 7.4 Hz, 1H), 6.87 (br s, 1H), 4.80 (dd, <ce:italic>J</ce:italic> = 13.6, 8.6 Hz, 1H), 4.64 (br s, 2H), 3.48 (s, 3H), 3.12 (dd, <ce:italic>J</ce:italic> = 14.9, 13.6 Hz, 1H), 2.70 (dd, <ce:italic>J</ce:italic> = 15.0, 8.6 Hz, 1H). <ce:sup loc="pre">13</ce:sup>C NMR (100.6 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> (ppm) 169.1, 160.9, 158.0, 157.7, 139.8, 135.9, 135.4, 135.3, 129.6, 129.1, 128.8, 128.2, 122.1, 119.0, 86.9, 43.5, 28.4, 22.7. IR (KBr) <ce:italic>ν</ce:italic> (cm<ce:sup loc="post">−1</ce:sup>): 3362, 3190, 1672, 1605, 1578, 1530, 1436, 1370, 1327, 1122, 779, 752, 693. MS (FAB) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> (%): 413.9 (100) [M+H]<ce:sup loc="post">+</ce:sup>, 399.9 (1), 378.0 (9). HRMS (FAB) calcd for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">18</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:sup loc="post">35</ce:sup>Cl<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup>: 414.0898; found: 414.0888. Anal. calculated for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">17</ce:inf>Cl<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">5</ce:inf>O: C 57.98, H 4.14, N 16.90; found: C 57.58, H 4.42, N 17.06.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.5" view="all">
                        <ce:label>4.1.5</ce:label>
                        <ce:section-title id="sectitle0100">2,4-Diamino-6-(2,6-dichlorophenyl)-5,6-dihydropyrido[2,3-d]pyrimidin-7(8H)-one (<ce:bold>12b</ce:bold>)</ce:section-title>
                        <ce:para id="p0205" view="all">A mixture of 1.08 g (12.01 mmol) of guanidine carbonate, 650 mg (12.03 mmol) of NaOMe and 15 mL of methanol was sealed in a 20 mL microwave vial and heated at 65 °C under microwave irradiation for 15 min. A clear solution with a white precipitate was obtained. The solid was removed by filtration and the mother liquor was transferred to a 20 mL microwave vial with a mixture of 920 mg (3.98 mmol) of methyl 2-(2,6-dichlorophenyl)acrylate and 316 mg (4.78 mmol) of malononitrile. The vial was sealed and heated at 140 °C under microwave irradiation for 10 min. The resulting precipitate was isolated by filtration, washed with water, EtOH and EtOEt and dried <ce:italic>in vacuo</ce:italic> over phosphorus pentoxide to afford 898 mg (2.77 mmol, 70%) of <ce:bold>12b</ce:bold> as a white solid. m.p. > 250 °C.</ce:para>
                        <ce:para id="p0210" view="all">
                           <ce:sup loc="pre">1</ce:sup>H NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> (ppm) 10.71 (br s, 1H), 7.58–7.48 (m, 2H), 7.37 (t, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 6.26 (br s, 2H), 6.04 (br s, 2H), 4.65 (dd, <ce:italic>J</ce:italic> = 13.1, 8.9 Hz, 1H), 2.88 (dd, <ce:italic>J</ce:italic> = 15.6, 8.9 Hz, 1H), 2.75 (dd, <ce:italic>J</ce:italic> = 15.5, 13.2 Hz, 1H). <ce:sup loc="pre">13</ce:sup>C NMR (100.6 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> (ppm) 170.1, 161.9, 161.8, 155.8, 135.6, 135.2, 134.8, 129.7, 128.3, 82.4, 43.3, 23.3. IR (KBr) <ce:italic>ν</ce:italic> (cm<ce:sup loc="post">−1</ce:sup>): 3471, 3367, 3209, 1672, 1627, 1564, 1453, 1383, 771. MS (EI) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> (%): 323.0 (40) [M]<ce:sup loc="post">+</ce:sup>, 288.1 (100) [M−HCl]<ce:sup loc="post">+</ce:sup>. Anal. calculated for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">11</ce:inf>N<ce:inf loc="post">5</ce:inf>OCl<ce:inf loc="post">2</ce:inf>: C 48.17, H 3.42, N 21.60; found: C 48.22, H 3.55, N 21.85.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.6" view="all">
                        <ce:label>4.1.6</ce:label>
                        <ce:section-title id="sectitle0105">6-(2,6-Dichlorophenyl)-N-phenyl-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diamine (<ce:bold>17</ce:bold>)</ce:section-title>
                        <ce:para id="p0215" view="all">3.6 mL (3.6 mmol) of borane tetrahydrofurane complex solution (1 M) were added to a solution of 240.2 mg (0.6 mmol) of <ce:bold>12a</ce:bold> in 4 mL of anhydrous THF. The solution was stirred at 50 °C for 3 days under nitrogen atmosphere. The solvent was removed <ce:italic>in vacuo</ce:italic> and the crude material was diluted with 2.5 mL of 6 M HCl and then refluxed for 30 min. After cooling to room temperature, the pH was adjusted to 7–8 with a NaOH (6 M) solution. The resulting solid was filtered and washed with cold water. The residue was purified by recrystallization from THF-cyclohexane to give 134.0 mg (0.35 mmol, 58%) of <ce:bold>17</ce:bold> as a yellowish solid. m.p. = dec at 192 °C.</ce:para>
                        <ce:para id="p0220" view="all">
                           <ce:sup loc="pre">1</ce:sup>H NMR (400 MHz, TFA-<ce:italic>d</ce:italic>) <ce:italic>δ</ce:italic> (ppm) 7.62–7.46 (m, 3H), 7.46–7.22 (m, 4H), 7.21–7.12 (m, 1H), 4.54–4.34 (m, 1H), 4.32–4.16 (m, 1H), 3.62 (m, 1H), 3.47 (t, <ce:italic>J</ce:italic> = 13.7 Hz, 1H), 2.59 (d, <ce:italic>J</ce:italic> = 12.2 Hz, 1H). <ce:sup loc="pre">13</ce:sup>C NMR (100.6 MHz, TFA-<ce:italic>d</ce:italic>) <ce:italic>δ</ce:italic> (ppm) 153.3, 152.2, 150.2, 138.3, 136.7, 134.3, 133.6, 133.3, 132.6, 131.7, 131.2, 128.6, 83.2, 43.8, 35.9, 22.2. IR (KBr) <ce:italic>ν</ce:italic> (cm<ce:sup loc="post">−1</ce:sup>): 3187, 2926, 1630, 1596, 1575, 1498, 1434, 1381, 1348, 1288, 758. MS (EI) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> (%): 385.1 (13) [M]<ce:sup loc="post">+</ce:sup>, 350.1 (17). HRMS (EI) calcd for C<ce:inf loc="post">19</ce:inf>H<ce:inf loc="post">17</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:sup loc="post">35</ce:sup>Cl<ce:inf loc="post">2</ce:inf> [M]<ce:sup loc="post">+</ce:sup>: 385.0861; found: 385.0851.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.7" view="all">
                        <ce:label>4.1.7</ce:label>
                        <ce:section-title id="sectitle0110">4-Amino-2-(4-bromophenylamino)-6-(2,6-dichlorophenyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (<ce:bold>18</ce:bold>)</ce:section-title>
                        <ce:para id="p0225" view="all">A dispersion of 412.3 mg (1.0 mmol) of <ce:bold>16</ce:bold> in 40 mL of acetic acid was treated with 0.50 mL (1.0 mmol) of 2 M bromine in acetic acid for 2 h at rt. The resulting solution was diluted with 1,4-dioxane (40 mL) and the solvent was removed by vacuum azeotropic distillation. A second 1,4-dioxane addition (40 mL) and vacuum distillation yields a white solid that is dispersed in water with ultrasounds and mechanical stirring. The resulting precipitate was filtered, washed with water and dried <ce:italic>in vacuo</ce:italic> over phosphorus pentoxide to afford 490.2 mg (0.5 mmol, 100%) of <ce:bold>18</ce:bold> as a white solid. m.p. = 267–269 °C.</ce:para>
                        <ce:para id="p0230" view="all">
                           <ce:sup loc="pre">1</ce:sup>H NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> (ppm) 9.67 (br s, 1H), 8.14 (s, 1H), 7.82 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 2H), 7.58 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H) 7.57 (br s, 2H), 7.51–7.37 (m, 3H), 3.61 (s, 3H). <ce:sup loc="pre">13</ce:sup>C NMR (100.6 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> (ppm) 161.1, 160.4, 158.1, 155.9, 139.5, 135.3, 135.1, 133.9, 131.2, 130.4, 128.1, 121.6, 120.6, 113.4, 91.7, 28.5. IR (KBr) <ce:italic>ν</ce:italic> (cm<ce:sup loc="post">−1</ce:sup>): 3414, 3074, 1616, 1584, 1549, 1520, 1488, 1463, 1431, 1412, 1351, 1197, 1008, 796. MS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> (%): 490.0 (61) [M+H]<ce:sup loc="post">+</ce:sup>. HRMS (ESI-TOF) calcd for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">15</ce:inf>N<ce:inf loc="post">5</ce:inf>O<ce:sup loc="post">79</ce:sup>Br<ce:sup loc="post">35</ce:sup>Cl<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup>: 489.9832; found: 489.9846. Anal. calculated for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">14</ce:inf>BrCl<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">5</ce:inf>O·HBr: C 41.99, H 2.64, N 12.24; found: C 41.87, H 2.70, N 11.83.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.8" view="all">
                        <ce:label>4.1.8</ce:label>
                        <ce:section-title id="sectitle0115">4-Amino-6-(2,6-dichlorophenyl)-8-methyl-2-[4-(4-methylpiperazin-1-yl)phenylamino]-pyrido[2,3-d]pyrimidin-7(8H)-one (<ce:bold>19</ce:bold>)</ce:section-title>
                        <ce:para id="p0235" view="all">A mixture of 196.4 mg (0.4 mmol) of <ce:bold>18</ce:bold>, 92.0 mg (0.8 mmol) of <ce:small-caps>l</ce:small-caps>-proline, 76.0 mg (0.4 mmol) of copper iodide, 63.4 mg (0.46 mmol) of Na<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> and 437.7 μL (7.82 mmol) of 1-methylpiperazine in 4.6 mL of DMSO was heated under microwave irradiation for 16 h at 80 °C. The resulting solution was cooled and water (400 mL) was added. The resulting precipitate was filtered, washed with water and dried <ce:italic>in vacuo</ce:italic> over phosphorus pentoxide to afford 140.0 mg (0.27 mmol, 69%) of <ce:bold>19</ce:bold> as a slightly brownish solid. m.p. = 220–222 °C.</ce:para>
                        <ce:para id="p0240" view="all">
                           <ce:sup loc="pre">1</ce:sup>H NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> (ppm) 9.21 (br s, 1H), 8.07 (s, 1H), 7.64 (d, <ce:italic>J</ce:italic> = 9.1 Hz, 2H), 7.60–7.55 (m, 2H), 7.43 (dd, <ce:italic>J</ce:italic> = 8.7, 7.5 Hz, 1H), 7.30 (br s, 2H), 6.89 (d, <ce:italic>J</ce:italic> = 9.1 Hz, 2H), 3.58 (s, 3H), 3.12–3.03 (m, 4H), 2.48–2.41 (m, 4H), 2.22 (s, 3H). <ce:sup loc="pre">13</ce:sup>C NMR (100.6 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> (ppm) 161.6, 160.5, 159.1, 156.1, 146.4, 135.4, 134.0, 132.3, 130.2, 128.4, 128.0, 120.9, 119.5, 115.7, 91.4, 54.7, 48.8, 45.8, 28.3. IR (KBr) <ce:italic>ν</ce:italic> (cm<ce:sup loc="post">−1</ce:sup>): 3405, 2927, 2799, 1633, 1575, 1514, 1464, 1426, 1236, 1193, 1147, 1008, 921, 800. MS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> (%): 510.2 (100) [M+H]<ce:sup loc="post">+</ce:sup>. HRMS (ESI-TOF) calcd for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">26</ce:inf>N<ce:inf loc="post">7</ce:inf>O<ce:sup loc="post">35</ce:sup>Cl<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup>: 510.1570; found: 510.1581. Anal. calculated for C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">25</ce:inf>Cl<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">7</ce:inf>O: C 58.83, H 4.94, N 19.21; found: C 58.36, H 5.09, N 19.02.</ce:para>
                        <ce:para id="p0245" view="all">
                           <ce:bold>19</ce:bold> was converted in the corresponding dimesylate salt <ce:bold>19</ce:bold>·(<ce:bold>MsOH</ce:bold>)<ce:inf loc="post">2</ce:inf> as follows: 382.8 mg (0.75 mmol) of <ce:bold>19</ce:bold> were dissolved in 50 mL of acetone and then 144.3 mg (1.5 mmol) of methanesulfonic acid were added. The resulting solution was stirred at room temperature for 2 h and then, cold diethyl ether was added and the resulting precipitated was filtered, washed with cold diethyl ether and dried <ce:italic>in vacuo</ce:italic> over phosphorus pentoxide to afford 456.7 mg (0.65 mmol, 87%) of 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one dimesylate <ce:bold>19</ce:bold>·(<ce:bold>MsOH</ce:bold>)<ce:inf loc="post">2</ce:inf> as a yellowish solid.</ce:para>
                        <ce:para id="p0250" view="all">
                           <ce:sup loc="pre">1</ce:sup>H NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 9.53 (br s, 2H), 9.34 (br s, 1H), 8.09 (s, 1H), 7.70 (d, <ce:italic>J</ce:italic> = 9.1 Hz, 2H), 7.59–7.56 (m, 2H), 7.44 (dd, <ce:italic>J</ce:italic> = 8.7, 7.5 Hz, 1H), 7.43 (br s, 2H), 6.98 (d, <ce:italic>J</ce:italic> = 9.2 Hz, 2H), 3.77 (d, <ce:italic>J</ce:italic> = 13.5 Hz, 2H) 3.59 (s, 3H), 3.52 (d, <ce:italic>J</ce:italic> = 11.9 Hz, 2H) 3.24–3.11 (m, 2H), 2.98–2.84 (m, 5H), 2.34 (s, 6H).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.9" view="all">
                        <ce:label>4.1.9</ce:label>
                        <ce:section-title id="sectitle0120">4-Amino-6-(2,6-dichlorophenyl)-8-methyl-2-[4-(2-morpholinoethylamino)-phenylamino]-pyrido[2,3-d]pyrimidin-7(8H)-one (<ce:bold>20</ce:bold>)</ce:section-title>
                        <ce:para id="p0255" view="all">A mixture of 98.2 mg (0.2 mmol) of <ce:bold>18</ce:bold>, 46.0 mg (0.4 mmol) of <ce:small-caps>l</ce:small-caps>-proline, 38.0 mg (0.2 mmol) of copper iodide, 31.7 mg (0.23 mmol) of Na<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> and 513.15 μL (3.91 mmol) of 4-(aminoethyl)morpholine in 2.3 mL of DMSO was heated under microwave irradiation for 16 h at 80 °C. The resulting solution was cooled and water (400 mL) was added. The resulting precipitate was filtered, washed with water and dried <ce:italic>in vacuo</ce:italic> over phosphorus pentoxide to afford 82.9 mg (0.15 mmol, 77%) of <ce:bold>20</ce:bold> as a slightly brownish solid. dec at 154 °C.</ce:para>
                        <ce:para id="p0260" view="all">
                           <ce:sup loc="pre">1</ce:sup>H NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> (ppm) 9.02 (br s, 1H), 8.04 (s, 1H), 7.56 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 7.47 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 2H), 7.42 (dd, <ce:italic>J</ce:italic> = 8.6, 7.5 Hz, 1H), 7.24 (br s, 2H), 6.56 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H), 5.13 (br t, <ce:italic>J</ce:italic> = 5.5 Hz, 1H), 3.59 (t, <ce:italic>J</ce:italic> = 4.6 Hz, 4H), 3.55 (s, 3H), 3.11 (dt, <ce:italic>J</ce:italic> = 6.3, 6.2 Hz, 2H), 2.50 (m, 2H), 2.41 (m, 4H). <ce:sup loc="pre">13</ce:sup>C NMR (100.6 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> (ppm) 161.6, 160.5, 159.2, 156.2, 144.5, 135.5, 134.0, 130.2, 129.4, 128.0, 121.9, 119.1, 112.0, 91.2, 66.2, 57.3, 53.4, 40.5, 28.2. IR (KBr) <ce:italic>ν</ce:italic> (cm<ce:sup loc="post">−1</ce:sup>): 3348, 2925, 2854, 1634, 1576, 1557, 1516, 1462, 1300, 1267, 1194, 1115, 1010, 800, 556. MS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> (%): 540.2 (100) [M+H]<ce:sup loc="post">+</ce:sup>, 453.1 (11). HRMS (ESI-TOF) calcd for C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">28</ce:inf>N<ce:inf loc="post">7</ce:inf>O<ce:inf loc="post">2</ce:inf>
                           <ce:sup loc="post">35</ce:sup>Cl<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup>: 540.1676; found: 540.1684. Anal. calculated for C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">27</ce:inf>Cl<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">7</ce:inf>O<ce:inf loc="post">2</ce:inf>: C 57.78, H 5.04, N 18.14; found: C 57.74, H 5.15, N 18.40.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.10" view="all">
                        <ce:label>4.1.10</ce:label>
                        <ce:section-title id="sectitle0125">4-Amino-6-(2,6-dichlorophenyl)-8-methyl-2-[4-(2-morpholinoethoxy)-phenylamino]-pyrido[2,3-d]pyrimidin-7(8H)-one (<ce:bold>21</ce:bold>)</ce:section-title>
                        <ce:para id="p0265" view="all">A mixture of 98.2 mg (0.2 mmol) of <ce:bold>18</ce:bold>, 38.0 mg (0.2 mmol) of copper iodide, 128.0 mg (0.4 mmol) of Cs<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> and 1.25 mL (8.80 mmol) of 4-(2-hydroxyethyl)morpholine was heated under microwave irradiation for 18 h at 180 °C. The resulting solution was cooled and water (400 mL) was added. The resulting precipitate was filtered, washed with water and dried <ce:italic>in vacuo</ce:italic> over phosphorus pentoxide. The residue was purified by flash chromatography (silica, CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>–MeOH; 100:0 to 90:10 in 18 min) to afford 18.9 mg (0.036 mmol, 18%) of <ce:bold>21</ce:bold> as a white solid.</ce:para>
                        <ce:para id="p0270" view="all">
                           <ce:sup loc="pre">1</ce:sup>H NMR (400 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> (ppm) 9.28 (br s, 1H), 8.08 (s, 1H), 7.70 (d, <ce:italic>J</ce:italic> = 9.1 Hz, 2H), 7.60–7.54 (m, 2H), 7.43 (dd, <ce:italic>J</ce:italic> = 8.7, 7.5 Hz, 1H), 7.33 (br s, 2H), 6.89 (d, <ce:italic>J</ce:italic> = 9.1 Hz, 2H), 4.06 (t, <ce:italic>J</ce:italic> = 5.8 Hz, 2H), 3.65–3.53 (m, 7H), 2.68 (t, <ce:italic>J</ce:italic> = 5.8 Hz, 2H), 2.49–2.44 (m, 4H). <ce:sup loc="pre">13</ce:sup>C NMR (100.6 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>) <ce:italic>δ</ce:italic> (ppm) 161.6, 160.5, 159.1, 156.1, 153.6, 135.4, 134.0, 133.5, 130.2, 128.0, 121.3, 119.6, 114.3, 91.4, 66.2, 65.5, 57.1, 53.7, 28.3. IR (KBr) <ce:italic>ν</ce:italic> (cm<ce:sup loc="post">−1</ce:sup>): 3410, 2926, 1633, 1576, 1557, 1525, 1508, 1464, 1422, 1228, 1196, 1114, 1011, 800. MS (ESI-TOF) <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic> (%): 541.2 (100) [M+H]<ce:sup loc="post">+</ce:sup>. HRMS (ESI-TOF) calcd for C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">27</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">3</ce:inf>
                           <ce:sup loc="post">35</ce:sup>Cl<ce:inf loc="post">2</ce:inf> [M+H]<ce:sup loc="post">+</ce:sup>: 541.1516; found: 541.1522. Anal. calculated for C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">26</ce:inf>Cl<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">6</ce:inf>O<ce:inf loc="post">3</ce:inf>: C 57.68, H 4.84, N 15.52; found: C 57.69, H 4.55, N 15.45.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0130">Biology</ce:section-title>
                     <ce:section id="sec4.2.1" view="all">
                        <ce:label>4.2.1</ce:label>
                        <ce:section-title id="sectitle0135">Kinase inhibition profile</ce:section-title>
                        <ce:para id="p0275" view="all">The kinase inhibition profile of compounds was evaluated at Proqinase (<ce:inter-ref xlink:href="http://www.proqinase.com" id="intref0015" xlink:type="simple">http://www.proqinase.com</ce:inter-ref>) by measuring residual activity values at a concentration of 10 μM of the test compound in singlicate in front of the following kinases: Btk, Lyn, Syk aa1-635 using the following protocol: The compounds were dissolved to 1 × 10<ce:sup loc="post">−3</ce:sup> M stock solutions in 100% DMSO. Subsequently, 100 μL of each stock solution were transferred into wells A3-F12 of a microtiter plate (“master plate”). Wells A1-F2 were filled with 100 μL 100% DMSO as controls. 5 × 10 μL of the master plate were aliquoted into 5 copy plates, which were stored at −20 °C until use. For the testing of each group of up to 8 kinases, one copy plate was used. In the process, 90 μL H<ce:inf loc="post">2</ce:inf>O were added to each well of a copy plate. To minimize precipitation, the H<ce:inf loc="post">2</ce:inf>O was added to each well only a few minutes before the transfer of the compound solutions into the assay plates. The plate was shaken thoroughly, resulting in a “compound dilution plate” with a compound concentration of 1 × 10<ce:sup loc="post">−04</ce:sup> M/10% DMSO. This plate was used for the transfer of 5 μL compound solution into the assay plates. The final volume of the assay was 50 μL. All compounds were tested at 1 × 10<ce:sup loc="post">−05</ce:sup> M in singlicate. The final DMSO concentration in the reaction cocktails was 1% in all cases. The compound dilution plates were disposed at the end of each working day.</ce:para>
                        <ce:para id="p0280" view="all">A radiometric protein kinase assay (<ce:sup loc="pre">33</ce:sup>PanQinase<ce:sup loc="post">®</ce:sup> Activity Assay) was used for measuring the kinase activity of the corresponding protein kinases. All kinase assays were performed in 96-well FlashPlatesTM from Perkin Elmer (Boston, MA, USA) in a 50 μL reaction volume. The reaction cocktail was pipetted in 4 steps in the following order: 10 μL of non-radioactive ATP solution (in H<ce:inf loc="post">2</ce:inf>O); 25 μL of assay buffer/[γ-33P]-ATP mixture; 5 μL of test sample in 10% DMSO; 10 μL of enzyme/substrate mixture. The assay for all protein kinases contained 70 mM HEPES-NaOH pH 7.5, 3 mM MgCl<ce:inf loc="post">2</ce:inf>, 3 mM MnCl<ce:inf loc="post">2</ce:inf>, 3 μM Na-orthovanadate, 1.2 mM DTT, ATP (variable amounts, corresponding to the apparent ATP-Km of the respective kinase), [γ-<ce:sup loc="pre">33</ce:sup>P]-ATP (approx. 8 × 10<ce:sup loc="post">05</ce:sup> cpm per well), protein kinase (variable amounts), and substrate (variable amounts). The protein kinase reaction cocktails were incubated at 30 °C for 60 min. The reaction was stopped with 50 μL of 2% (v/v) H<ce:inf loc="post">3</ce:inf>PO<ce:inf loc="post">4</ce:inf>, plates were aspirated and washed two times with 200 μL 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of <ce:sup loc="pre">33</ce:sup>Pi (counting of “cpm”) was determined with a microplate scintillation counter (Microbeta, Wallac). All protein kinase assays were performed with a BeckmanCoulter Core robotic system.</ce:para>
                        <ce:para id="p0285" view="all">For each kinase, the median value of the cpm of six wells of column 1 of each assay plate was defined as “low control” (<ce:italic>n</ce:italic> = 6). This value reflects unspecific binding of radioactivity to the plate in the absence of a protein kinase but in the presence of the substrate. Additionally, for each kinase the median value of the cpm of six wells of column 2 of each assay plate was taken as the “high control”, i.e. full activity in the absence of any inhibitor (<ce:italic>n</ce:italic> = 6). The difference between high and low control of each enzyme was taken as 100% activity. As part of the data evaluation the low control of each kinase was subtracted from the high control value as well as from their corresponding “compound values”. The residual activity (in %) for each compound well was calculated by using the following formula:<ce:display>
                              <ce:formula id="ufd1">
                                 <mml:math altimg="si1.gif" overflow="scroll">
                                    <mml:mrow>
                                       <mml:mtext>Res</mml:mtext>
                                       <mml:mtext>.</mml:mtext>
                                       <mml:mspace width="0.25em"/></mml:mspace>
                                       <mml:mtext>Activity</mml:mtext>
                                       <mml:mo>(</mml:mo>
                                       <mml:mo>%</mml:mo>
                                       <mml:mo>)</mml:mo>
                                       <mml:mo>=</mml:mo>
                                       <mml:mn>100</mml:mn>
                                       <mml:mo>×</mml:mo>
                                       <mml:mo>[</mml:mo>
                                       <mml:mrow>
                                          <mml:mrow>
                                             <mml:mo>(</mml:mo>
                                             <mml:mtext>signal</mml:mtext>
                                             <mml:mspace width="0.25em"/></mml:mspace>
                                             <mml:mtext>of</mml:mtext>
                                             <mml:mspace width="0.25em"/></mml:mspace>
                                             <mml:mtext>compound</mml:mtext>
                                             <mml:mo>−</mml:mo>
                                             <mml:mtext>low</mml:mtext>
                                             <mml:mspace width="0.25em"/></mml:mspace>
                                             <mml:mtext>control</mml:mtext>
                                             <mml:mo>)</mml:mo>
                                          </mml:mrow>
                                          <mml:mo>/</mml:mo>
                                          <mml:mrow>
                                             <mml:mo>(</mml:mo>
                                             <mml:mtext>high</mml:mtext>
                                             <mml:mspace width="0.25em"/></mml:mspace>
                                             <mml:mtext>control</mml:mtext>
                                             <mml:mo>−</mml:mo>
                                             <mml:mtext>low</mml:mtext>
                                             <mml:mspace width="0.25em"/></mml:mspace>
                                             <mml:mtext>control</mml:mtext>
                                             <mml:mo>)</mml:mo>
                                          </mml:mrow>
                                       </mml:mrow>
                                       <mml:mo>]</mml:mo>
                                    </mml:mrow>
                                 </mml:math>
                              </ce:formula>
                           </ce:display>
                        </ce:para>
                        <ce:para id="p0290" view="all">As a parameter for assay quality, the Z′-factor <ce:cross-ref refid="bib26" id="crosref0315">[26]</ce:cross-ref> for the low and high controls of each assay plate (<ce:italic>n</ce:italic> = 8) was used. ProQinase's criterion for repetition of an assay plate is a Z′-factor below 0.4 <ce:cross-ref refid="bib27" id="crosref0320">[27]</ce:cross-ref>. Z′-factors did not drop below 0.51, indicating an excellent assay quality.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.2" view="all">
                        <ce:label>4.2.2</ce:label>
                        <ce:section-title id="sectitle0140">Assays in non-Hodgkin's lymphomas cell lines and on the activity of BCR kinases</ce:section-title>
                        <ce:para id="p0295" view="all">Cell culture: cell lines were grown in suitable culture media at 37 °C in a humidified atmosphere containing 5% CO<ce:inf loc="post">2</ce:inf>. The following MCL cell lines were used in the assays: Rec-1, HBL-2, UPN-1, Jeko-1, JVM-2, Maver-1, Mino, Granta-519, and Z-138. The following CLL cell lines were used in the assays: MEC-2, JVM-13, and MEC-1. The following FL cell lines were used in the assays: DoHH-2, WSU-NHL, WSU-FSCCL, and SC-1. The following DLBCL cell lines were used in the assays: OCI-LY8, SUDHL-8, U-2932, and SUDHL-16. The following media were used for the indicated cell lines: RPMI 1640 + 10% foetal bovine serum (FBS) for Rec-1, HBL-2, UPN-1, JVM-2, MAVER, Z138, Mino, JVM-13, WSU-NHL, WSU-FSCCL, DOHH2, SC-1 and U2932; RPMI 1640 + 20% FBS for Jeko-1, SUDHL-8 and SUDHL-16; DMEM +10%FBS for Granta-519; IMDM +10% FBS for MEC-1 and MEC-2; IMDM+20% FBS for OCI-LY8.</ce:para>
                        <ce:para id="p0300" view="all">Analysis of the growth inhibition was carried out using the MTT (Thiazolyl Blue Tetrazolium Bromide) proliferation assay: cells grown in exponential phase were seeded in 96 well plates at 0.5 × 10<ce:sup loc="post">6</ce:sup> cell/ml and treated with compounds <ce:bold>12b</ce:bold>, <ce:bold>14a</ce:bold>, <ce:bold>15</ce:bold>, <ce:bold>16</ce:bold>, <ce:bold>17</ce:bold>, <ce:bold>19</ce:bold>, <ce:bold>20</ce:bold> and <ce:bold>21</ce:bold> at the doses of 0.1, 0.5, 1, 5, 10, 20, 50 and 100 μM, or with ibrutinib or R406 (Selleck Chemicals) at the indicated doses. After 24 h or 48 h, MTT reagent was added to each well, incubated for 2 h at 37 °C and plates were then read in a Synergy-HT Multi-Mode Microplate Reader (Biotek). The GI<ce:inf loc="post">50</ce:inf> (concentration of drug required to reduce cell growth by 50%) was calculated from the cytotoxic values obtained by incubating cells with the indicated doses of the drug using GraphPad Prism software version 4.0.</ce:para>
                        <ce:para id="p0305" view="all">Analysis of B-Cell Receptor (BCR) activation signaling molecules by Western Blot and flow cytometry. Total protein extracts in 1% Triton X-100 plus protease and phosphatase inhibitors were made from cells exposed to the indicated treatment. These cells lysates were resolved by standard SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis), transferred to PVDF (polyvinylidene difluoride) membranes and incubated overnight with antibodies against pSyk, pLyn and pBtk (Cell Signaling Technology) or β-actin (Sigma) followed by species-matched secondary horseradish peroxidase (HRP)-labeled antibodies. Chemiluminiscence was developed adding enhanced chemilumiscence (ECL) reagent and signal was captured in a LAS4000 device using Image Gauge software (Fujifilm). In parallel, intracellular amount of PhosphoY223-Btk was determined by immunostaining with an anti-phosphoY223-Btk-PE antibody (clone N35-86), using IgG1 κ isotype-PE as negative control (BD Biosciences). After treatment, cells (5 × 10<ce:sup loc="post">5</ce:sup>) were fixed in 4% paraformaldehyde in PBS (15 min, 4 °C), permeabilized with cold methanol (10 min, −20 °C), washed with PBS containing 1% BSA and incubated with the indicated antibodies at room temperature for 15 min. Finally, cells were washed with PBS containing 1% BSA, resuspended in 500 μL PBS and analyzed by flow cytometry in an Attune acoustic focusing cytometer (Life Technologies). The Mean Fluorescence Ratio (MFIR) between the mean fluorescence intensity of Btk-PE signal and isotypic control was then calculated for both untreated and treated conditions. These MFIR were then referred to the untreated control (r).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.3" view="all">
                        <ce:label>4.2.3</ce:label>
                        <ce:section-title id="sectitle0145">Cytotoxicity assay in PBMCs isolated from healthy donors</ce:section-title>
                        <ce:para id="p0310" view="all">In accordance with the guidelines of the Ethical Committee of the Hospital Clínic in Barcelona (Spain), mononuclear cells were isolated from peripheral blood of two healthy voluntaries by Ficoll/Hypaque sedimentation (GE Healthcare) and conserved within the Hematopathology Biobank of our institution (Biobanks from CDB-IDIBAPS-Hospital Clínic). Cells were cryopreserved before using in liquid nitrogen in the presence of 10% dimethyl sulfoxide, 60% FBS and 30% RPMI 1640. Once thawed, cells were cultured in complete RPMI medium at a density of 10<ce:sup loc="post">6</ce:sup> cells/ml and treated as indicated. Cell viability was evaluated by exclusion of apoptotic cells by double staining with annexin V conjugated to fluorescein isothiocyanate (FITC) and propidium iodide (PI) (Bender Medsystems) as described <ce:cross-ref refid="bib28" id="crosref0325">[28]</ce:cross-ref>. Ten thousand stained cells per sample were acquired and analyzed in an Attune acoustic focusing cytometer using Attune software (Life Technologies).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.4" view="all">
                        <ce:label>4.2.4</ce:label>
                        <ce:section-title id="sectitle0150">Statistical analysis</ce:section-title>
                        <ce:para id="p0315" view="all">Comparisons between two groups of samples were evaluated by the Student's <ce:italic>t</ce:italic>-test, using GraphPad Prism 4.0 software (GraphPad Software, Inc.).</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.3" view="all">
                     <ce:label>4.3</ce:label>
                     <ce:section-title id="sectitle0155">Computational studies</ce:section-title>
                     <ce:para id="p0320" view="all">Computational blind docking and ligand binding within the binding pockets of Btk, Syk, and Lyn kinases was carried out using the Btk kinase domain complexed with 2-[4-(2-diethylamino-ethoxy)-phenylamino]-6-(4-fluorophenoxy)-8-methyl-8<ce:italic>H</ce:italic>-pyrido[2,3-<ce:italic>d</ce:italic>]pyrimidin-7-one (PDB ID: <ce:inter-ref xlink:href="pdb:3PJ2" id="intref0020" xlink:type="simple">3PJ2</ce:inter-ref>) <ce:cross-ref refid="bib22" id="crosref0330">[22]</ce:cross-ref>, the Syk kinase domain complexed with <ce:italic>N</ce:italic>-(4-methyl-3-(8-methyl-7-oxo-2-(phenylamino)-7,8-dihydropyrido[2,3-<ce:italic>d</ce:italic>]pyrimidin-6-yl)phenyl)-3-(trifluoromethyl)benzamide (PDB: <ce:inter-ref xlink:href="pdb:3TUD" id="intref0025" xlink:type="simple">3TUD</ce:inter-ref>) <ce:cross-ref refid="bib23" id="crosref0335">[23]</ce:cross-ref>, and the Lyn kinase domain-dasatinib complex (PDB: <ce:inter-ref xlink:href="pdb:2ZVA" id="intref0030" xlink:type="simple">2ZVA</ce:inter-ref>) <ce:cross-ref refid="bib24" id="crosref0340">[24]</ce:cross-ref>, respectively.</ce:para>
                     <ce:para id="p0325" view="all">Dockings were analyzed in detail by using AutoDock Tools 1.5.6 <ce:cross-ref refid="bib29" id="crosref0345">[29]</ce:cross-ref> and AutoDock 4.2 <ce:cross-ref refid="bib30" id="crosref0350">[30]</ce:cross-ref> to study the interactions between <ce:bold>19</ce:bold> and the three kinase domains. To perform these calculations, the compound <ce:bold>19</ce:bold> structure was built, assigned Gasteiger partial charges <ce:cross-ref refid="bib31" id="crosref0355">[31]</ce:cross-ref> and minimized in MOE 2012.10 <ce:cross-ref refid="bib32" id="crosref0360">[32]</ce:cross-ref> with the MMFF94 force field. For the AutoDock blind docking experiments, 5 torsions were selected for structure <ce:bold>19</ce:bold>, a 60.60.60 grid with a grid spacing of 0.375 was used, and was centered on the defined ligand-binding sites of the three kinase structures. In each case, 100 independent Lamarckian genetic algorithm (LGA) runs were performed and pseudo-Solis and Wets minimization methods were applied by using default parameters.</ce:para>
                  </ce:section>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0160">Acknowledgment</ce:section-title>
               <ce:para id="p0330" view="all">The authors appreciate the financial support from the <ce:grant-sponsor id="gs1" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Spanish Ministerio de Economía y Competitividad</ce:grant-sponsor> projects <ce:grant-number refid="gs1">SAF2010-C21617-C02</ce:grant-number> (J.I.B.), <ce:grant-number refid="gs1">SAF 09/9503</ce:grant-number> and <ce:grant-number refid="gs1">SAF 12/31242</ce:grant-number> (D.C.), <ce:grant-number refid="gs1">SAF 11/29326</ce:grant-number> (P.P.-G.), <ce:grant-sponsor id="gs2" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Redes Temáticas de Investigación Cooperativa de Cáncer from the Instituto de Salud Carlos III</ce:grant-sponsor> (<ce:grant-number refid="gs2">RD2006/20/014</ce:grant-number> and <ce:grant-number refid="gs2">RD12/0036/0004</ce:grant-number>) and <ce:grant-sponsor id="gs3" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Generalitat de Catalunya</ce:grant-sponsor> 
                  <ce:grant-number refid="gs3">2009SGR967</ce:grant-number> (D.C.), <ce:grant-sponsor id="gs4" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Fondo de Investigación Sanitaria, European Regional Development Fund (ERDF)</ce:grant-sponsor> “Una manera de hacer Europa” grants <ce:grant-number refid="gs4">PI09/0060</ce:grant-number> and <ce:grant-number refid="gs4">PI12/01847</ce:grant-number> (G.R.). R. Puig de la Bellacasa wants to thank Generalitat de Catalunya for a grant within the Talent empresa (TEM) 2009 program (2009 TEM 00128).</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0165">Supplementary data</ce:section-title>
                  <ce:para id="p0335" view="all">Spectral data for compounds <ce:bold>14a</ce:bold>, <ce:bold>15</ce:bold>, <ce:bold>16</ce:bold>, <ce:bold>17</ce:bold>, <ce:bold>12b</ce:bold>, <ce:bold>18</ce:bold>, <ce:bold>19</ce:bold>, <ce:bold>20</ce:bold>, and <ce:bold>21</ce:bold>.<ce:display>
                        <ce:e-component id="ec1">
                           <ce:link locator="mmc1"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0170">Supplementary data</ce:section-title>
                  <ce:para id="p0340" view="all">Supplementary data related to this article can be found at <ce:inter-ref xlink:href="doi:10.1016/j.ejmech.2014.09.018" id="intref0035" xlink:type="simple">http://dx.doi.org/10.1016/j.ejmech.2014.09.018</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0175">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Nogai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Dorken</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Lenz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pathogenesis of non-Hodgkin's lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1803</sb:first-page>
                              <sb:last-page>1811</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Tilly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dreyling</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>v172</sb:first-page>
                              <sb:last-page>v174</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kridel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.H.</ce:given-name>
                                 <ce:surname>Sehn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.D.</ce:given-name>
                                 <ce:surname>Gascoyne</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pathogenesis of follicular lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Invest</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>122</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3424</sb:first-page>
                              <sb:last-page>3431</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Jares</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Colomer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Campo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular pathogenesis of mantle cell lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Invest</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>122</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3416</sb:first-page>
                              <sb:last-page>3423</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Zenz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Mertens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kuppers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Döhner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Stilgenbauer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>From pathogenesis to treatment of chronic lymphocytic leukaemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>37</sb:first-page>
                              <sb:last-page>50</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Young</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Staudt</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting pathological B cell receptor signalling in lymphoid malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug. Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>3</sb:issue-nr>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>229</sb:first-page>
                              <sb:last-page>243</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Quintás-Cardama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kantarjian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cortes</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Future Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>655</sb:first-page>
                              <sb:last-page>665</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Hantschel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Rix</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Schmidt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Bürckstümmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kneidinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Schütze</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Colinge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.L.</ce:given-name>
                                 <ce:surname>Bennett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Ellmeier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Valent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Superti-Furga</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U S A</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>104</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>13283</sb:first-page>
                              <sb:last-page>13288</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.C.</ce:given-name>
                                 <ce:surname>Amrein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.C.</ce:given-name>
                                 <ce:surname>Attar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Takvorian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.P.</ce:given-name>
                                 <ce:surname>Hochberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Ballen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Leahy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Fisher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Lacasce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.D.</ce:given-name>
                                 <ce:surname>Jacobsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Armand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.P.</ce:given-name>
                                 <ce:surname>Hasserjian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Werner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Neuberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2977</sb:first-page>
                              <sb:last-page>2986</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Friedberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sharman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sweetenham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.B.</ce:given-name>
                                 <ce:surname>Johnston</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Vose</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lacasce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schaefer-Cutillo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>De Vos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sinha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Leonard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.D.</ce:given-name>
                                 <ce:surname>Cripe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Gregory</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.P.</ce:given-name>
                                 <ce:surname>Sterba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Lowe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Levy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Shipp</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of Syk with fostamatinib disodium has significant clinical activity in non Hodgkin's lymphoma and chronic lymphocytic leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>115</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2578</sb:first-page>
                              <sb:last-page>2585</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.H.</ce:given-name>
                                 <ce:surname>Advani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Buggy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Sharman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.E.</ce:given-name>
                                 <ce:surname>Boyd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Grant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Kolibaba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.R.</ce:given-name>
                                 <ce:surname>Furman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rodriguez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.Y.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sukbuntherng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Izumi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hamdy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Hedrick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.H.</ce:given-name>
                                 <ce:surname>Fowler</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>88</sb:first-page>
                              <sb:last-page>94</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Byrd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.R.</ce:given-name>
                                 <ce:surname>Furman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Coutre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.W.</ce:given-name>
                                 <ce:surname>Flinn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Burger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Blum</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Grant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Sharman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Coleman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Wierda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Jones</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.A.</ce:given-name>
                                 <ce:surname>Heerema</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sukbuntherng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.Y.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Clow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Hedrick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Buggy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.F.</ce:given-name>
                                 <ce:surname>James</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>O'Brien</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>369</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>32</sb:first-page>
                              <sb:last-page>42</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rule</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Martin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Goy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Auer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.S.</ce:given-name>
                                 <ce:surname>Kahl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Jurczak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.H.</ce:given-name>
                                 <ce:surname>Advani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Romaguera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Barrientos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Chmielowska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Radford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Stilgenbauer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dreyling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.W.</ce:given-name>
                                 <ce:surname>Jedrzejczak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Spurgeon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Newberry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Ou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Fang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>McGreivy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Clow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Buggy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.Y.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Beaupre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Kunkel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Blum</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>369</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>507</sb:first-page>
                              <sb:last-page>516</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Yao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Geng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6368</sb:first-page>
                              <sb:last-page>6372</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Martínez-Teipel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Teixidó</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Pascual</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mora</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Pujolà</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Fujimoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.I.</ce:given-name>
                                 <ce:surname>Borrell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.L.</ce:given-name>
                                 <ce:surname>Michelotti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>2-Methoxy-6-oxo-1,4,5,6-tetrahydropyridine-3-carbonitriles: versatile starting materials for the synthesis of libraries with diverse heterocyclic scaffolds</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comb. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>436</sb:first-page>
                              <sb:last-page>448</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:comment>(and the references therein)</sb:comment>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Victory</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Nomen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Colomina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Garriga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Crespo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>New synthesis of pyrido[2,3-d]pyrimidines. 1. Reaction of 6-alkoxy-5-cyano-3,4-dihydro-2-pyridones with guanidine and cyanamide</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Heterocycles</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>1985</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1135</sb:first-page>
                              <sb:last-page>1141</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Perez-Pi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Berzosa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Galve</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Teixido</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.I.</ce:given-name>
                                 <ce:surname>Borrell</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dehydrogenation of 5,6-dihydropyrido[3,2-d]pyrimidin-7(8H)-ones: a convenient last step for a synthesis of pyrido[2,3-d]pyrimidin-7(8H)-ones</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Heterocycles</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>82</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>581</sb:first-page>
                              <sb:last-page>591</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Galve</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Puig de la Bellacasa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sanchez-Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Batllori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Teixidó</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.I.</ce:given-name>
                                 <ce:surname>Borrell</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis of 2-arylamino substituted 5,6-dihydropyrido[2,3-d]pyrimidine-7(8H)-ones from arylguanidines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Diver</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>639</sb:first-page>
                              <sb:last-page>649</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.H.</ce:given-name>
                                 <ce:surname>Boschelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Klutchko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.D.H.</ce:given-name>
                                 <ce:surname>Showalter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Hamby</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.H.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.C.</ce:given-name>
                                 <ce:surname>Major</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.K.</ce:given-name>
                                 <ce:surname>Dahring</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Batley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Panek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Keiser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.G.</ce:given-name>
                                 <ce:surname>Hartl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Kraker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.D.</ce:given-name>
                                 <ce:surname>Klohs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.J.</ce:given-name>
                                 <ce:surname>Roberts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Patmore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.L.</ce:given-name>
                                 <ce:surname>Elliott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Steinkampf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Bradford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hallak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Doherty</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>41</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4365</sb:first-page>
                              <sb:last-page>4377</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <ce:other-ref id="oref1">
                        <ce:textref>J.J. Liu, K.C. Luk, 5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones, US7098332(B2), August 29, 2006 (CAN 141:71554).</ce:textref>
                     </ce:other-ref>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Roué</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Pérez-Galán</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mozos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>López-Guerra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Xargay-Torrent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Rosich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Saborit-Villarroya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Normant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Campo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Colomer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>117</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1270</sb:first-page>
                              <sb:last-page>1279</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kuglstatter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Tsing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Lou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Villasenor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Bradshaw</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Shaw</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Barnett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Browner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Protein Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>428</sb:first-page>
                              <sb:last-page>436</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Lovering</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>McDonald</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Whitlock</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Glossop</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Phillips</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Sabnis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ryan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Fitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kurumbail</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Thorarensen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of type-II inhibitors using kinase structures</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol. Drug. Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>80</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>657</sb:first-page>
                              <sb:last-page>664</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.K.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.S.</ce:given-name>
                                 <ce:surname>Lucet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.P.</ce:given-name>
                                 <ce:surname>Klinken</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Ingley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Rossjohn</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>284</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>284</sb:first-page>
                              <sb:last-page>291</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <ce:other-ref id="oref2">
                        <ce:textref>J.I. Borrell, J. Teixidó, R. Puig de la Bellacasa, D. Colomer, G. Roué, P. Pérez-Galán, 4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof, EP 13382225, June 14th, 2013.</ce:textref>
                     </ce:other-ref>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.D.</ce:given-name>
                                 <ce:surname>Chung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Oldenburg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A simple statistical parameter for use in evaluation and validation of high throughput screening assays</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biomol. Screen</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>67</sb:first-page>
                              <sb:last-page>73</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.W.</ce:given-name>
                                 <ce:surname>Iversen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.J.</ce:given-name>
                                 <ce:surname>Eastwood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Sittampalam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.L.</ce:given-name>
                                 <ce:surname>Cox</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A comparison of assay performance measures in screening assays: signal window, Z' factor, and assay variability ratio</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biomol. Screen</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>247</sb:first-page>
                              <sb:last-page>252</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Rosich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Xargay-Torrent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>López-Guerra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Campo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Colomer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Roué</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5278</sb:first-page>
                              <sb:last-page>5289</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Sanner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Python: a programming language for software integration and development</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Mol. Graph. Mod.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>57</sb:first-page>
                              <sb:last-page>61</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Morris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Huey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Lindstrom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Sanner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.K.</ce:given-name>
                                 <ce:surname>Belew</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Goodsell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Olson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2785</sb:first-page>
                              <sb:last-page>2791</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Gasteiger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Marsili</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Iterative partial equalization of orbital – electronegativity – a rapid access to atomic charges</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tetrahedron</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>1980</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3219</sb:first-page>
                              <sb:last-page>3228</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref30">
                        <sb:comment>2013.08</sb:comment>
                        <sb:host>
                           <sb:book>
                              <sb:title>
                                 <sb:maintitle>Molecular Operating Environment (MOE)</sb:maintitle>
                              </sb:title>
                              <sb:date>2013</sb:date>
                              <sb:publisher>
                                 <sb:name>Chemical Computing Group Inc.</sb:name>
                                 <sb:location>1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>